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CHAPTER 1 
INTRODUCTION 

1 Introduction 
When no lymph node metastases are detected clinically in patients with head 
and neck cancer, the neck is staged as NO (42). The elective treatment of the NO 
neck, by either surgery or radiotherapy, results in excellent local control rates (2,4, 
7,29). This thesis specifically deals with the use of radiotherapy as a single modality 
treatment for the clinically negative neck. Given the risk of radiation-induced side 
effects, elective neck irradiation is advocated in many institutions only if the proba-
bility of subclinical disease is considered to be more than 10-20% (31). The major 
side effects of the elective irradiation of the neck are the dry mouth syndrome 
(xerostomia) and dental caries due to damage to the major and minor salivary 
glands. 
A major advance in radiotherapy in the last decade has been the development 
and clinical implementation of conformal radiotherapy. With the introduction of 
three-dimensional CT-based radiotherapy planning systems, it has become feasible 
to conform the high dose region to the target volume. In case of elective neck irra-
diation for example, high doses of radiation can be delivered to the neck with spar-
ing of the salivary glands and other normal tissues such as the spinal cord. The main 
objective of this thesis is to provide a three-dimensional CT definition of the target 
of the NO neck which will indeed allow the design of conformal radiotherapy tech-
niques for elective neck irradiation. It is defined and presented in such a way that it 
can be studied and verified interactively on CD-i. 
The second goal of this thesis is the development of conformal radiotherapy treat-
ment plans and subsequently, to demonstrate the potential for reducing the side 
effects of elective neck irradiation by using such conformal techniques. The cover-
age of the three-dimensional NO neck target and the amount of sparing of the 
parotid (and submandibular) salivary glands can subsequently be studied interac-
tively with a CD-i, using all CT-, MRI- and anatomical slices obtained from a human 
cadaver. 
In Chapter 2, clinical aspects relevant to the treatment of the NO neck are sum-
marized. In addition, the basic radiobiological postulates pertinent to the subject of 
subclinical disease and also the rationale and treatment principles of conformal 
radiotherapy are discussed in detail. 
In Chapter 3, the outcome of a nationwide survey in The Netherlands on the 
elective neck target volume is reported. Treatment fields for the NO neck were 
planned, using conventional techniques according to institutional preferences, for 
tumors located in the mobile tongue and supraglottic larynx by a number of Dutch 
radiation oncologists. The results highlight the need for better guidelines on the def-
inition of neck nodal regions. 
In Chapter 4, detailed proposals for a CT definition of the three-dimensional neck 
target are presented; this data and the way they were obtained were incorporated 
into the CD-i. 
Subsequently, in Chapter 5, three-dimensional treatment planning aspects regard-
ing conformal radiotherapy of the NO neck are presented. Dose distributions of con-
ventional and three-dimensional conformal treatment plans are shown and com-
pared interactively on CD-i. 
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Chapter 6 describes how the data which was presented in Chapters 4 and 5 were 
implemented on CD-i. The purpose of making available the thesis data on CD-i was 
to provide the tools for the study of the three-dimensional CT target definition of 
the neck in a user-friendly self-assessment program, in an interactive manner. In 
addition the tools were provided for the reproduction of the three-dimensional CT 
target definition, to verify the definition given in Chapter 4. 
The work for this thesis is part of an on-going project at the Daniel den Hoed 
Cancer Center in Rotterdam involving the development of conformal radiotherapy 
techniques on a MM50 Racetrack Microtron. The dual gantry MM50 Racetrack 
Microtron, which has been in operation in our institution since March 1994, is a 
fully computer-controlled treatment unit and is eminently suited for advanced con-
formal radiotherapy techniques. Photon beams can be produced between 10 to 50 
MV, in steps of 5 MV Electron beams are available from 7.5 to 50 MeV with a step 
size of 2.5 MeV The system is equipped with double focused multi leaf collimators. 
For both electron and photon beams, flat beam profiles are created by scanning of 
elementary beams according to fixed scanning patterns. Due to the beam scanning, 
flattening filters for photon beams can be omitted (or limited to very thin filters), 
yielding extremely flat beam profiles at all depths. For electron beams, the applied 
scattering foils are very thin. The combination of beam scanning, thin scattering foils 
and the presence of helium in the treatment head enables the use of high energy 
electron beams in isocentric irradiation techniques, with the multileaf collimator 
acting as a beam shaping device. Intensity modulated beams can be generated by 
computer-controlled superposition of multileaf collimator-defined fields, by the 
scanning of elementary beams according to individualized scanning patterns, and by 
dynamic multi leaf collimation. 
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CHAPTER 2 
THE CLINICALLY NEGATIVE NECK 
SCOPE OF THE PROBLEM 

2 The clinically negative neck - scope of the problem 
2.1 Clinical aspects 
Curability of patients with tumors in the head and neck is dependent on factors 
such as patient characteristics, tumor biology and the specifics of the treatment tech-
nique. In patients with head and neck cancer, the development of lymph node 
metastases in the neck (and thus the presence of subclinical disease) has proven to 
be an extremely important prognostic parameter for predicting loco-regional failure 
and/or development of distant metastases (11,38,40,46). The risks for subclinical 
disease in a clinically negative neck can be derived from the reported incidence of 
pathologically positive nodes found after elective neck dissection for particular 
tumor sites (and stages) and/or estimated from the conversion rate of a untreated 
clinically negative neck into a positive neck, that is, a neck with metastatic deposits 
in the regional lymph nodes (see Table 2-1). 
Table 2w 1. Incidence of lymph node metastases in a clinically negative neck 
with no neck treatment (after Mendenhall et al.) (29). 
Site 
Floor of Mouth 
Gingiva 
Hard Palate 
Buccal Mucosa 
Oral Tongue 
Nasopharynx 
Retromolar Trigone 
Soft Palate 
Tonsillar Fossa 
Supraglottic Larynx 
Conversion Rate [%J 
20-35 
17 
22 
16 
38-52 
19-50 
10-15 
16-25 
22 
33 
A high risk for lymph nodal involvement has been found to be associated with 
histology (e.g. undifferentiated squamous cell carcinoma) and size (e.g. advanced 
T-stage) of the primary tumor (26). The relative density of capillary lymphatics at the 
site of the primary tumor site also plays an important role in the potential for dis-
semination of the cancer cells to the regional lymph nodes. For example, the 
nasopharynx and piriform sinus have the most profound capillary lymphatic net-
works in contrast to the middle ear, paranasal sinuses and vocal cords which have 
very few capillary lymphatics. This is in agreement with the high- and low incidence, 
respectively, of lymph node metastases found at presentation when the primary 
tumor is confined to these tumor sites (29). Finally, pathological examination of neck 
dissection specimen has shown an orderly and predictable progression of lymph 
nodal involvement (39). The neck nodes are usually divided into the submental 
nodes, the submandibular nodes, the junctional nodes, the subdigastric nodes, the 
middle- and lower jugular nodes, and the posterior neck nodes; or, as is most fre-
quentlythe case in the surgical literature, into levels I-VI (see Figure 2-1) (37). 
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Figure 2-1. Lymph node levels in the neck after Shah et al. (37). 
2.2 Diagnostic aspects 
The detection of lymph node metastases in the neck is crucial for the appropri-
ate management of the disease. There are several ways to examine the neck; clini-
cal palpation, CT scanning, magnetic resonance imaging (MRI), ultrasound (US) and 
ultrasound fine needle aspiration cytology (USFNAC). Although not completely reli-
able, because of its simplicity palpation is still an important and certainly the most 
used diagnostic procedure. In recent years, the combination of US and fine needle 
aspiration cytological examination of suspected lymph nodes has dramatically 
improved the assessment of lymph node metastases in the neck. For example, in 
Table 2-2, the accuracy, sensitivity and specificity for the different diagnostic means 
as reported by van den Brekel et aI., is presented (45). Micrometastases may, how-
ever, still be missed because of sampling errors. For instance, Brennan et al. identi-
fied, using molecular analysis techniques for p53 mutations, tumor cells in 6 out of 
28 lymph nodes that were initially found to be negative by pathological examina-
tion (6). 
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Table 2-2. Accuracy of diagnostic procedures in staging of the neck. 
Method Accuracy 1%1 Sensitivity [%] Specificity ['Yo] 
USFNC 93 90 100 
MRI 
CT 
US 
Palpation 
82 
78 
75 
69 
82 
83 
75 
67 
81 
70 
75 
73 
2.3 Clinical management - general aspects 
Controversy still exists with regards to the optimal treatment of the clinically neg-
ative neck. An important aspect of elective neck treatment is the small (or non-exist-
ing) tumor-load present at the time the treatment, and thus, a high regional control 
rate can be expected from either surgery or radiotherapy. This has indeed been sub-
stantiated by many publications, where well over 90% regional control rates have 
been reported for the two modalities (2,4,7,29). Patients without lymph node 
metastases are treated unnecessarily. This is of particular relevance since both 
surgery and radiotherapy are not without side effects. On the other hand, if neck 
nodes show up after a wait and see policy, only about 60% (somewhat depending 
on the primary tumor site) will be controlled by a subsequent therapeutic neck dis-
section. In other words, not all patients are salvaged after a policy of watchful wait-
ing (24). Moreover, it has been argued that failure to treat the neck electively may 
lead to an increased risk for dissemination to distant sites (21,29). Other disadvan-
tages of a wait and see policy are the need for a more extensive follow up and the 
psychological uncertainty about the ultimate outcome for patients, and also their 
doctors. 
Table 2-3. Relation between types of neck dissection (NO) and the removal 
(yes or no) of the submandibular gland{s) for different head and neck tumor 
sites. 
Type of neck dissection 
Functional NO 
Radical ND 
Supra-omohyoidal NO 
Selective NO 
Anterior NO 
Resection of the submandibular gland{s) 
Larynx All other sites 
no yes 
yes yes 
no yes 
no yes I no 
no no 
The choice whether to irradiate the neck electively or to perform an elective neck 
dissection is also dependent on a number of factors. Next to subjective arguments 
such as institutional (doctors) preferences, the decision depends also on the treat-
ment modality used for the primary cancer. For reviews on the matter the reader is 
referred to Nahum et al. and to Baatenburg de jong et al. (1,33). Elective neck dis-
section almost always constitutes resection of one or both submandibular glands 
(see Table 2-3). This will result in a significant decrease in salivary flow rate, with 
approximately one third of the patients developing xerostomia, particularly at nights 
and dental carious lesions (20). Despite the drawbacks, radiotherapy still plays an 
important role in the clinical management of the NO neck and is usually recom-
mended if the estimated risk of neck disease exceeds 10-20%. The aim of this the-
sis is to improve on the radiotherapy techniques used for elective neck irradiation, 
i.e. to decrease the associated normal tissue toxicity, in particular with regard to the 
problem of xerostomia. Moreover, by reducing the associated morbidity neck irra-
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diation, being non-invasive, will continue to remain one of the mainstays in the 
elective neck treatment armament. 
2.4 Clinical management - radiotherapeutic aspects 
2.4.1 Target definition 
In the treatment of cancers of the head and neck by ionizing radiation, one aims 
for loco- regional control of the disease with minimal damage to the surrounding 
normal tissues . In order to achieve an optimal result a precise definition of the tar-
get volume is mandatory. In this thesis, the ICRU-SO recommendations for the tar-
get defin ition are adopted (19). These are summarized in Figure 2-2. 
Figure 2-2. Definition of the target volumes according to the 
ICRU-50 guidelines. (19) GTV: gross tumor volume, CTV: 
clinical target volume, PTV: planning target volume, TV: 
treated volume, IV: irradiated volume. 
The gross tumor volume (GTV) denotes the visible or palpable tumor. The clini-
cal target volume (CTV) stands for the GTV and an estimated margin for subclinical 
spread of the disease. The volume of the neck considered to be at risk for subclini-
cal disease is also called CT\I. The plann ing target volume (PTV) is a geometrical con-
cept and consists of the CTV and a margin to account for (daily) variations of the 
CTV in size, shape, and position relative to the treatment beam(s). The PTV may 
even extend outs ide the body of a patient. The treated volume is the volume that 
receives a radiation dose that is considered important for loco-regional control or 
cure. The irradiated volume is the volume that receives a dose which is considered 
important in relation to normal tissue tolerance. 
2.4.2 Dose~response 
Radiobiologi ca l data ind icates that radiation cell kill is basically exponential; i.e. 
a given dose results in the kil l of a proportion of tumor cells. Of particular relevance 
are the surviving tumor cells which are capable of regenerating the tumor, i.e. clono-
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Figure 2-3. Dose-response relationship in head and neck 
tumors treated by radiotherapy only using a continuous 
course technique. Figure 2-3 was taken from original publica-
tion (see also Addendum A, this thesis) 
genic cells. For a given tumor size, the probability of eradicating all cionogenic cells 
increases with higher doses (so-called dose-response curve). Many reports highlight 
the existence of these dose-response relationships (35,41). For example, a retro-
spective study of 1493 head and neck cancer patients was performed to test this 
radiobiological postulate at the Daniel den Hoed Cancer Center / University 
Hospital Rotterdam (DHCC/UHR). Primary squamous cell carcinomas of the head 
and neck which were irradiated to a dose of at least 50 Gy, were analyzed. In 
Figures 2-3 and 2-4 the probability of local relapse at 3 years is shown as a function 
of normalized treatment dose (NTD) for T1/T2 versus n/T4 tumor stages, treated 
by continuous course radiotherapy (CC-RT; Figure 2-3) or split course radiotherapy 
(SC-RT; Figure 2-4), respectively. With the exceptions of a small subset of T1/T2 CC-
RT patients, the data summarized by both figures indeed generate evidence for the 
Split Course RT 
T1 fT2 and T3fT 4 tumors 
100 
" 
75 .. .. .. (e) 
~ .. (I) (9) m 
00 
~ T3,T4 • <Jj 50 
'" • u (i) 
.3 
" 
25 ..... -T.1 ,T2 
0 
SO 60 70 80 
NTD [Gy] 
Figure 2-4. Dose-response relationship in head and neck 
tumors treated by radiotherapy only using a split course tech-
nique. Figure 2-4 was taken from original publication (see 
also Addendum A, this thesis) 
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existence of a dose-response relationship in gross disease. A more detailed analysis 
of the results is given in the paper as reported in Addendum A. 
Table 2-4. Control rates for subclinical disease in the neck (13,25,30). 
Dose / Treatment Duration 
30 Gy I 3 weeks 
40 Gy I 4 weeks 
45-50 Gy I 5 weeks 
Regional Control Rates 
70 % 
80-90 % 
95 % 
As mentioned previously, the diagnostic procedures to detect lymph node metas-
tases in the neck are far from being accurate. Moreover, even the pathological 
examination of neck dissection specimens can miss lymph node metastases. 
Consequently, the tumor-load of patients with occult neck disease may be more 
than "microscopic". Nevertheless, the maximum number of donogenic cells and, 
consequently, the dose needed to obtain regional control, will certainly be less than 
in case of a gross tumor volume (e.g. the primary tumor). In 1971, Berger et al. pro-
posed a dose of 45-50 Gy in to be delivered in 5 weeks for effective elective irradi-
ation of (parts of) the neck (4). In many institutions, this is still the recommended 
dose range for elective neck irradiation. In fact, as is the case for gross disease, a sig-
moidal dose response curve for subclinical disease in the neck is apparent from data 
in the literature. Table 2-4 indicates the approximate regional control rates for elec-
tive neck irradiation as a function of dose. 
2.4.3 Side effects 
The side effects of the irradiation of healthy tissues can be divided into two cat-
egories: acute and late injuries. Generally there is no correlation between these two 
types of injuries, and the severity of the acute reactions does not necessarily predict 
for the severity of the late sequelae. 
In head and neck cancer, acute effects mostly result from damage to the skin and 
mucous membranes, and are usually of a temporary nature. Depending on treat-
ment techniques (e.g. dose to the skin, field size, overall treatment time) and patient 
factors (e.g. site, degree of pigmentation of the skin), the skin reactions range from 
erythema, dry desquamation to moist desquamation. Healing is almost always com-
plete within 2-4 weeks after treatment. The mucosal side effects manifest 1 week 
after start of the treatment with erythema. Mucositis is present at the end of the sec-
ond week and is accompanied by a sore throat which is usually most severe 2,/, to 
3 weeks after the start of the treatment. The mucous membranes normally heal 2,/, 
to 3 weeks following radiotherapy. The loss of taste generally begins in the second 
week of a course of radiotherapy, and rapidly progresses after 20 Gy. Taste acuity 
will recover to a large extent after the end of radiotherapy, and recovery is usually 
complete between 60 to 120 days post treatment. However, a subjective loss of 
taste with little or no tendency for improvement is sometimes reported by patients. 
The latter is believed to be at least partially due to xerostomia. 
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Xerostomia is a late side effect which causes severe discomfOit to the patients 
because of the dry mouth per se and because of a difficulty in swallowing. The 
reduction in salivary flow also decreases taste acuity and contributes to dental decay. 
Salivary gland dysfunction has its onset during the course of radiotherapy and is usu-
ally permanent and complete after doses of more than 40 Gy have been applied. 
Since the reduction of this extremely troublesome clinical problem is pertinent to 
the goal of this thesis, a few relevant reports of the literature on this subject are dis-
cussed in more detail. For example, Leslie and Dische reported a volume response 
and a dose response relationship in the changes of the parotid flow during the first 
months after the end of the treatment (23). Doses exceeding 40 Gy produced a 
complete loss of salivary flow. In contrast, if 50% or less of the parotid glands were 
included in the irradiated high dose volume, the loss of flow rate 8 weeks after the 
end of radiotherapy was less than 50% of the pre-treatment flow rate. Mira et al. 
showed that doses of 30 to 40 Gy to all salivary gland tissue were capable of induc-
ing minimal flow rates with no recovery seen at 1 to 17 months after treatment (32). 
In the first 12 months post treatment, Makkonen et al. observed partial recovery of 
salivary flow rates after doses of 31 to 46 Gy to the salivary glands (27). However, 
the authors noted that in their cases, the upper (cranial) parts of the parotid glands 
were usually found to be outside the radiation portals. Many authors have claimed 
that the parotid glands are responsible for most of the saliva production. Ferguson 
showed that this is particularly true for the stimulated salivary gland flow (12). 
During sleep and in rest, however, it is believed that the submandibular glands con-
tribute most to the total flow produced by the salivary glands (20). In fact, it is not 
uncommon for patients to wake up at night because of a severe dry mouth. 
Therefore, special attention is given in this thesis to the geographical position of both 
the parotid- and the submandibular glands in relation to the irradiated volume. 
Finally, high-dose irradiation to gross disease can produce late sequelae like sub-
cutaneous fibrosis, fibrosis of muscles and even ulceration or necrosis of soft tissues 
and bone. Other critical structures, that can be injured by high dose irradiation are 
the thyroid gland, ear, spinal cord, brain, cranial nerves (including the visual path-
ways) and pituitary gland. However, as the doses used in elective irradiation of the 
neck typically vary between 40 to 50 Gy, i.e. well below the tolerance levels of 
many of these tissues, a detailed account of all such side effects is beyond the scope 
of this thesis. This thesis will highlight the late sequelae due to the irradiation of the 
major sal ivary glands. 
2.4.4 Treatment techniques ~ conformal radiotherapy 
The most commonly used technique in head and neck cancer utilizes parallel 
opposed portals, with or without an abutted low anterior portal. This can have 
major disadvantages, regarding side effects (e.g. xerostomia, see Chapter 2.4.3) and 
target coverage. With respect to target coverage (that is too Iowa dose to the target 
- see also Chapter 2.4.2), major emphasis is given at present to three-dimensional 
conformal radiotherapy techniques. With the development of sophisticated multi-
ple beam treatment plans, the three-dimensional target can be adequately treated 
to high doses of irradiation whilst minimizing the dose to normal tissues. 
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Figure 2-5. Basic principles 01 conformal radiotherapy. A: multiple non-opposing fields, B: 
beam's eye view-blocks (mullileaf collimator) , C: beam intensity modulation (e.g. dynam-
ic multileaf collimator, missing tissue compensator). 0 : minimizing patients 'setup errors. 
See text for explanation. 
The current literature on conformal radiotherapy focuses mainly on the use of 
sophisticated conformal radiotherapy treatment techniques for the primary (gross) 
tumor volum'e, i.e. for relatively limited target volumes. In the majority of patien ts, 
however, it is not desirable (or even feasib le) to irradiate the primary tumor and 
neck as separate entities. Therefore, the premise for developing a sophisticated elec-
tive neck irradiation technique in order to spare critica l structu res slich as (part of) 
the major salivary glands, implies that a conformal treatment technique (porta ls) 
shou ld adequately cover the primary (gross) tumor volume as well , and vice versa . 
The intricate relationship between the primary cancer and the neck is an obvious 
limitation for treatment techniques, in particular those which are conventional tech-
niques. However, with conformal radiotherapy techniques a number of improve-
ments can be anticipated in this regard (see also Chapter 5). 
In conformal radiotherapy, a treatment plan is deSigned using a three-dimen-
sional target defined on CT slices. For elective neck irradiation, the contours of the 
primary tumor as wel l as of the node negative neck (CTV) have to be delineated on 
every CT slice. In order to conform the high dose radiation area to the three-dimen-
sional target volume with optimal sparing of the normal tissues, SOme basic princi-
ples of conformal radiotherapy are important. 
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Firstly, radiation fields produce a high dose in the overlapping field region. The 
use of multiple non-opposing, non co-planar portals smears out the dose outside 
the PTV sparing the normal tissues, as schematically illustrated in Figu re 2-5A. 
Next, beam's eye view graphics and use of customized blocks or a mu ltileaf col-
limator make it feasible to choose and shape portals such that the irrad iation of crit-
ical normal structures can be avoided (Figure 2-5B). 
Th irdl y, it is also possible to change the beam intensity profile with so called beam 
intensity modifiers (Figure 2-5C; see also Chapter 5). This may allow to choose 
beams that avoid critical structures, and still be able to cover the target homoge-
neously. 
Finally, by the obligatory need for accurate t reatment setup techniques and by 
limiting th e day-to-day variations in patient positioning, margins around the CTV 
can be decreased. The resulting smaller PTV allows for the use of smal ler fie lds 
(Figu re 2-5D). 
An examp le of the potential benefits of conformal radiotherapy in primary head 
and neck cancers, is seen in the findings of a failure analysis performed on 109 
patients w ith squamous cell carcinoma of the piriform sinus (PS), who where treat-
ed between 1973-1984 in the DHCC!U HR (see also Addendum B). The incentive 
for the fa ilure analysis per se was the apparent poor results obta ined in PS cancer 
treated by radiotherapy only, i .e. a 5-year loco-regiona l relapse free survival of on ly 
40% was observed. However, when a PS cancer treatment plan using conventional 
radiotherapy techn iques (Figure 2-6) was compared with a plan of the same tumor 
mass treated by conformal radiotherapy using beam intensity modifiers (Figure 2-7), 
at least three findings are obvious. Firstly, with the conventiona l parallel-opposed 
6 2 1 5 
4 3 
I I 
" 
(1,2) 
" '" 
'" 
,,, 
[30) (5 ,6) 
Figure 2-6. Conventional technique (as used in study period 1973-1984): The tar-
get volume is irradiated by two parallel opposed wedged fields, using 4 MV pho-
Ions (fields 1 and 2); the lower neck (nodes) by an abutted anterior photon por-
tal (not depicted in the diagram). The posterior part of the piriform sinus lies in 
close proximity to the vertebra/cord. Afler a dose of 40 Gy, the spinal cord is 
shielded and the primary tumor is taken to 70 Gy (fields 5 and 6) . An ipsilateral 
low energy electron field (10 MeV) is added to the parallel opposed (blocked) 
photon fields to boost the posterior part of the primary tumor to a dose of 70 Gy 
(field 3); in · a number of patients the posterior contralateral neck was carried 
(electively) to a cumulative dose of 50 Gy (field 4). Figure 2-6 was taken from 
original publication (see also Addendum B, this thesis). 
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Figure 2-7. Example of stage 1111 piriform sinus cancer using three-dimensional 
conformal radiotherapy technique (future technique) . Same tumor as depicted in 
Figure 2-6 was hypothetically irradiated by a 5-field technique using beam inten-
sity modifiers. As is demonstrated in this schematic diagram, the target volume 
(primary tumor) can be easily taken to a cumulative dose of 70 Gy without over-
dosing the normal tissues. Figure 2-7 was taken from original publication (see 
also Addendum B, this thesis). 
treatment techniques used at the time of the study period, some parts of the pri-
mary tumor mass were underdosed. Secondly, dose escalation wou ld have been dif-
ficult without sign ificantly exceeding the tolerance of the cord. Finally, xerostomia 
was inevitable with the conventional technique because of the high doses delivered 
to large parts of the parotid glands. 
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Figure 2-8. Dose volume histograms for primary piriform sinus (PS) cancer, 
parotid gland (P) and cord (e), comparing conventional treatment technique dot-
ted lines; see Figure 2-6) and conformal radiotherapy using a 5-field technique 
with beam intensity modifiers (solid lines; see Figure 2-7). Figure 2-8 was taken 
from original publication (see also Addendum B, this thesis). 
In summary, the authors proposed that by using a multiple beam arrangement 
with beam intensity modifiers, increased loco-regional control rates could be 
achieved with reduced morbidity due to the sparing of the parotid glands (Figure 
2-8). A full account of the study is given in Addendum B. 
2.4.5 Quality assurance 
Conformal radiotherapy requires highly accurate techniques, both in the prepa-
ration phase and during the course of treatment. In general, errors that occur in the 
preparation phase will lead to systematic errors during the treatmenC whereas errors 
originating during the treatment can both be systematic and/or random. Treatment 
setup errors may occur in the preparation phase or during a course of radiotherapy. 
With the use of tighter margins and beam intensity modifiers in conformal radio-
therapy an error in beam positioning during treatment preparation can influence 
treatment outcome significantly. 
In order to evaluate the impact of such errors, the simulation accuracy for maxil-
lary sinus tumors has been studied in the DHCC/UHR. Five patients were planned 
as if they were to be treated for a maxillary sinus tumor. A three beam CT scan-
based computer calculation was performed for each patient. The position of the 
central beam axis of each beam, relative to bony anatomical landmarks/ was mea-
sured. Patients were then simulated using the bony references to position the radi-
ation beams. Subsequently, the simulation procedure was repeated with the use of 
a noninvasive external localization frame, with a known accuracy and reproducibil-
ity of < 2 mm (34). When defining the clinical target volume as the tumor with a 
1 cm margin, three of the five patients would have suffered a geographical miss 
throughout the entire radiation treatment course due to erroneous beam position-
ing at the simulation stage (Table 2-5). 
Table 2-5. Beam positioning errors expressed in mm at the time of simula-
tion of a maxillary sinus tumor, detected by a noninvasive external localiza-
tion frame. CC: cranio-caudal, AP: antero-posterior, SD: standard deviation. 
Table 2-5 was taken from original publication (see also Addendum C, this 
thesis). 
Left Beam Right Beam Anterior Beam 
CC AP CC AP CC LL 
Patient 1 -8 7 -8 16 -8 3 
Patient 2 -10 6 -10 -8 -10 10 
Patient 3 14 3 14 0 14 11 
Patient 4 -10 5 -10 -2 -10 0 
Patient 5 13 -5 3 3 13 6 
Mean (1-5) -0.2 3.2 -0.2 1.8 -0.2 6 
SD (1-5) 11.2 4.3 11 .2 8.0 11.2 4.1 
With regards to the normal tissues, the contra-lateral eye lens would have been 
irradiated to a considerable dose (expressed in a large normal tissue complication 
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probability (NTCP) value) in the two patients with the largest beam positioning 
errors. In contrast, the right eye lens (which would have received a full dose when 
irradiating according to the computer plan) was found to receive doses well below 
its tolerance level in the patients with the largest beam positioning errors (Table 2-6). 
Table 2-6. Tumor control probability (TCP)- and normal tissue complication 
probability (NTCP) values (or patients with maxillary sinus tumors when sim-
ulated and treated according to treatment plan (Intended plan: using the 
noninvasive external localization frame) or with simulation errors (patient 
1-5: simulating by anatol11icallandrnarks). Table 2-6 was taken from original 
publication (see also Addendum C, this thesis), 
TCP I%J NTCP I%J 
ipsilateral contralateral 
eye lens eye lens spinal cord 
Intended plan 77.6 100.0 7.2 0.0 
Patient 1 41.3 61.8 0.7 0.0 
Patient 2 22.5 1.6 0.2 0.1 
Patient 3 8.8 100.0 99.7 1.3 
Patient 4 47.2 7.0 0.1 0.0 
Patient 5 15.9 100.0 96.6 0.4 
Mean (1-5) 27.1 
These data clearly demonstrate that beam positioning errors during simulation are 
of particular clinical relevance and should be taken into serious consideration when 
defining a planning target volume if anatomical landmarks are to be used during 
simulation. The additional treatment margins needed for this reason have still to be 
decided upon and will probably vary according to tumor site, the treatment tech-
nique used, and whether or not correction protocols are implemented. A more 
detailed account of the study is given in the paper as reported in Addendum C. 
Portal films can be made in order to evaluate the positioning errors during a 
radiotherapy course. In a prospective study in the DHCC/UHR using portal films on 
tumors in the head and neck, the standard deviation of random positioning errors 
appeared to be 3 mm (18). The introduction of fast on-line electronic portal imag-
ing systems however, allows for improvement of patient set-up accuracy during the 
treatment course, minimizing both systematic and random positioning errors (8, 
10,28,47,50). The major disadvantage of such procedures is the considerable 
increase in treatment time. Bel et al. described a verification procedure to correct 
systematic deviations of patient set-up at an early stage during treatment, yielding a 
high overall set-up accuracy with a minimal workload (3). Using this procedure, the 
systematic errors in patient set-up become small compared to the random position-
ing errors during a radiotherapy course. In summary, the need for an additional mar-
gin around the CTV to account for systematic errors can probably be eliminated 
with portal imaging using a verification procedure. Random day-to-day patient posi-
tioning errors during treatment are measured with portal imaging, to verify that an 
adequate margin around the CTV was used during treatment planning. 
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2.4.6 Summary 
Chapter 2 describes the literature findings of elective treatment of the neck, in 
particular the treatment techniques and side effects of these treatments. From this 
review it is apparent that the use of conformal radiotherapy techniques might 
improve the therapeutic ratio. In order to implement conformal radiotherapy in 
elective neck irradiation one needs an adequate description of the three-dimen-
sional target of the neck on CT. This data is as yet unavailable; see also Chapter 3. 
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CHAPTER 3 
ELECTIVE NECK IRRADIATION 
CONVENTIONAL TECHNIQUES 

3 Elective neck irradiation - conventional techniques 
3.1 Introduction 
Standard treatment techniques have been used for elective neck irradiation over 
many years. For the conventional elective irradiation of both sides of the neck, two 
types of treatment techniques are in use. One consists of two lateral parallel 
opposed fields, and the other of lateral opposed fields with a matched anterior 
lower neck portal down to the clavicles. When using these techniques, the target 
(i.e. the node negative neck) is defined on simulation films. In defining the target, 
one (in principle) delineates the projection of a three-dimensional target on X-ray 
(simulation) films. Although the control rates after using such conventional tech-
niques are reported to be excellent, these are achieved with side-effects, and in par-
ticular xerostomia (see also Chapter 2). Since these side effects are related to the 
(excessive) amount of normal tissues irradiated, the question then arises as to 
whether the two-dimensional demarcations on simulation films really conform to 
the projections of the three-dimensional target. In other words, is there a good two-
dimensional target definition? To answer this question a study was performed to 
analyze the variations in applied treatment portals for elective neck irradiation in 
The Netherlands. 
3.2 Conventional portals in elective neck irradiation 
The variation among radiation oncologists in the choice of treatment portals for 
elective neck irradiation, and its consequences for the incidence of side effects, 
were analyzed by a nation-wide survey in The Netherlands. Two typical primary 
tumor sites were selected: a T2 mobile tongue carcinoma (MT), and a T3 cancer of 
the supraglottic larynx (SL), both without clinically detectable disease in the neck 
(NO). The patients were to be treated in supine position on a 6 MV linear accelera-
tor to a total dose of 46 Gy in fractions of 2 Gy, 5 times per week. The demarcating 
borders of the portals correspond to the 50% isodose line. Copies of lateral and 
anterior simulation films of a single patient, who was previously treated in the 
DHCC!UHR, were sent to 16 radiation oncologists in 11 Radiation-Oncology 
departments in The Netherlands. On these films, the radiation oncologists were 
asked to delineate their "routine" portals for elective neck irradiation of both pri-
mary tumor sites. A CT scan for planning purposes of the patient was only available 
to us (slices were taken every 5 mm in treatment position, using a Siemens Somatom 
Plus scanner). 
The delineated treatment portals were digitized in the DHCC/UHR and entered 
into the CAD PLAN three-dimensional planning system (version 2.61, Varian 
Dosetek). The CT data were also transmitted to CADPLAN. For both primary tumor 
sites (MT & SL) the radiation oncologists were divided into 2 groups, one using lat-
eral opposed fields only, the other using a combination of lateral opposed fields and 
an anterior field for the lower neck. The data were analyzed by superimposing all 
treatment portals (delineated by the radiation oncologists) on beam's eye view 
images of the patient, including the parotid- and submandibular glands. With 
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Figure 3-1. A nationwide survey on treatment porlals: the delineated treatment portals for a T2NQ mobile 
tongue cancer and a T3NO cancer of the supraglottic larynx of all participating radiation oncologists 
superimposed in beam's eye view on the patient anatomy, Le. the patient outline and the submandibu-
lar- and parotid glands for the lateral portals and the patient outline and the clavicles for the anterior por-
lals. Technique I: lateral parallel opposed portals only; Technique II : lateral parallel opposed portals in 
combination with an anterior portal. The scale (5 em) relates to a distance of 100 em from the focus. 
Figure 3-1 was taken from original publication (see also Addendum 0 , this thesis). For further explana-
tion , see text. 
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Figure 3-2_ Treated volumes, i.e. volumes receiving more than 95% of the pre-
scribed dose for Techniques I (blue) and II (yellow), in combination with min-
imum, maximum and median values. Figure 3-2 was taken from original pub-
lication (see also Addendum 0, this thesis) . For further explanation, see text. 
CAPLAN close distributions were calculated for all treatment plans using 6 MV pho-
ton beams (according to the treatment technique and portals selected by each indi-
vidua l radiation oncologist). The treated volume (see Chapter ), defined as the vol-
ume enclosed by the 95% isodose line, was calculated for every treatment plan. 
In addition, dose volume histogram analysis was performed for the parotid- and 
submandibular glands, together w ith an analysis of the NTCP va lues. In Figure 3-1, 
beam's eye view images of elective neck irradiation portals for cancer of the MT and 
SL are shown. The large variation in the size of the portals is apparent and indicates 
a lack of standardization. These differences can also be seen in the treated volumes 
(Figure 3-2). 
There are two possible explanations for the variation in treatment portals. Firstly, 
some radiation oncologists conceptually treat different lymph nodal groups in the 
neck for the same primary tumor stage. Secondly, there is disagreement on the geo-
graphical borders of these lymph nodal groups even if radiation oncologists intend 
to irradiate the same lymph nodal groups. The vast differences in the posterior bor-
der are indicative for the second argument in particular. The beam's eye view 
images also demonstrate that roughly one-half to two-thi rds of the parotid glands are 
with in the radiation fields; for a few portals both parotid glands are incorporated 
totally in the treated volume. The impact of the parotid gland volume included in 
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Figure 3-3. Normal tissue complication probability (NTCP) values of the left (blue) and right (red) 
parotid gland for a prescribed dose of 46 Gy to the neck. Figure 3-3 was taken from original publica-
tion (see also Addendum D, this thes is). For further explanation, see text. 
the irradiated volume can also be appreciated from the NTCP values shown III 
Figure 3-3. 
A detailed description and analysis of this study is presented in Addendum D. In 
summary: there appears to be no consensus between radiation oncologists as to the 
areas of the neck that need to be electively irrad iated for (at least) the prilllary tumor 
sites studied. A translation of the three-dimensional target, i.e. the potential lymph 
nodal "areas" (regions) of the neck, into a two-dilllensiona l target (delineation on 
silllulation filllls) is Illandatory. Following th is step, radiation oncologists wi ll need to 
decide (preferably by consensus) on the neck regions wh ich require irradiation's for 
any particular clin ical indication. This latter aspect of elective neck irradiation is, 
however, a subject beyond the scope of this thesis. 
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CHAPTER 4 
THREE-DIMENSIONAL CT TARGET DEFINITION 
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4 Three-dimensional CT target definition 
4.1 Introduction 
In order to define a three-dimensional CT definition of the elective neck, the fol-
lowing requirements were postulated. Firstly, the clinical target volume in surgery 
should in principle be similar to the CTV in radiotherapy, as elective neck dissection 
results in the same regional control rates as is the case with elective neck irradiation. 
Secondly, contouring of the target volume and critical structures on multiple CT 
slices should be fast with minimal risk for errors. This requires that the landmarks 
used be easily recognizable during the process of delineation of the target on CT, 
and this will also enhance reproducibility. Thirdly, the definition of the target should 
be given in treatment position of the neck. For elective neck irradiation, this refers 
to a supine position without rotation of the head, and is therefore somewhat distinct 
from the situation with surgery. Furthermore, it is postulated that subclinical disease 
respects natural borders like muscle compartments, bone and cartilage. 
The accuracy of the CT target definition should be easily verified. It was felt that 
the best way to achieve this goal, was to implement the CT target definition on CD-i 
together with the anatomical information that was obtained from a human cadaver 
study. The target definition in this chapter was given for CT as almost all three-
dimensional treatment planning systems only work with CT images. As these systems 
are rapidly evolving, and as it is to be expected that the target and critical structures 
in the near future will be delineated on CT and MRI, a matched MRI image for every 
CT image was included on the CD-i as well. 
4.2 Target definition - procedures and results 
4.2.1 Anatomical studies 
In order to be able to correlate the surgical borders of the levels (I-VI) with struc-
tures seen on CT and MRI, two anatomical studies were performed using fixed (phe-
nol, formaldehyde) human cadavers. 
Firstly, a modified radical neck dissection was performed by an ENT surgeon on 
a human cadaver. The sternocleidomastoid muscle and the spinal accessory nerve 
were spared. Borders of the levels I-VI were demarcated using plastic tubes filled 
with liquid fat. CT slices were obtained every 3 mm with a Siemens Somatom Plus 
scanner. Using the laser lights in the gantry of the CT scanner, the position of the first 
slice was marked. This position was reproduced when MRI scans were acquired 
(slices every 3 mm), using a Magnetom scanner (Siemens). This way matched trans-
verse CT- and MRI slices were obtained. 
The second human cadaver was immobilized on a wooden support using a 
polyurethane construction foam. Matched CT- and MRI slices (every 3 mm) were 
again obtained. Besides the CT- and MRI images, simulation films were also taken 
as is performed for conventional radiotherapy technique; i.e. two lateral opposed 
fields and an anterior portal for the lower neck. The cadaver was then frozen to 
minus 80" Celsius and sectioned into slices of 5 mm thickness, using an immobile 
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bandsaw. This cryosectioning procedure has been described by Entius et al. in detail 
(9). Directly following the cryosectioning, the slices were rinsed with cold water. 
After alignment with the previously added special demarcations, photographs were 
taken (35 mm color films). The photographs were digitized and stored on a photo· 
CD. The transversal CT·, MRI· and anatomical slices (photographs of the slices) were 
matched. From the matched CT- and MRI data, a matched CT· and MRI volume was 
reconstructed. Both volumes were then "software sectioned" to obtain matched 
frontal and sagittal CT· and MRI slices. The image editing was performed using the 
AVS visualization system (version 5.02 Advanced Visual Systems Inc.). 
Table 4~ 1. Lymph node classification system according to the level definition 
of the Memorial Sloan-Kettering group (37). 
Level Lymph nodes Borders 
IA Submental The anterior belly of the digastric muscles and the hyoid 
bone 
IB Submandibular The anterior and posterior bellies of the digastric muscle 
and the body of the mandible 
[[ Upper jugular Superior: skull base 
Inferior: carotid bifurcation (or hyoid bone) 
Anterior: lateral border sternohyoid muscle 
Posterior: posterior border sternocleidomastoid muscle 
III Middle jugular Superior: carotid bifurcation (or hyoid bone) 
Inferior: omohyoid muscle (or cricothyroid notch) 
Anterior: lateral border sternohyoid muscle 
Posterior: posterior border sternocleidomastoid muscle 
IV Lower jugular Superior: omohyoid muscle (or cricothyroid notch) 
Inferior: clavicle 
Anterior: latera! border ~ternohyoid muscle 
Posterior: posterior border sternocleidomastoid muscle 
V Posterior triangle Inferior: clavicle 
Anterior: 
Posterior: 
VI Anterior Superior: 
Inferior: 
Lateral: 
posterior border sternocleidomastoid muscle 
anterior border trapezius muscle 
hyoid bone 
suprastemal notch 
medial borders carotid sheath 
4.2.2 Surgical definition ~ levels 
The backbone for the current three·dimensional CT definition was an official 
report of the American Academy of Otolaryngology·Head and Neck Surgery, which 
was released in 1991 (36). With respect to the level definition, the most important 
objectives of the Subcommittee for Neck Dissection Nomenclature were to define 
the clinical and surgical borders of each of the lymph nodal groups to be removed 
with the neck dissection specimen, and to develop a classification that correlates 
with current oncological principles in the head and neck. The lymph nodal groups 
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were classified according to the level system as originally described by the Memorial 
Sloan-Kettering Croup (37). The level classification was designed for surgical proce-
dures and is defined by using many soft tissue landmarks (muscles, carotid bifurca-
tion etc.), as summarized in Table 4-1. Unfortunately, many of the listed anatomical 
structures are not easily distinguishable on CT and, therefore, are not particularly 
suitable for translation into a CT target definition. 
4.2.3 Target borders on anatomical slices 
Using the data from the first anatomical study, for every anatomical slice the cra-
nial-, caudal-, ventral-, dorsal-, medial- and lateral borders of levels, corresponding 
to the surgical borders of the level definition of the Memorial Sloan-Kettering group, 
were demarcated, in close cooperation with the otolaryngologist and the radiologist. 
The demarcated tissue boundaries (Table 4-2) correspond exactly to the original 
level definition, except for the cranial border of level II; that is, for the cranial bor-
der of level II the transverse process of vertebra C-II in stead of base of skull was 
chosen. 
4.2.4 Target borders on CT slices 
The second anatomical study was used to find the borders on corresponding CT 
slices; after some adjustments, the delineated CT slices were subsequently imple-
mented on a CD-i. The adjustments of the borders had to be made in order to arrive 
at the CT target definition. Because of the albeit slight adjustments, the lymph node 
levels in the neck are designated as "regions". With respect to the target of the NO 
neck, only fatty tissue in between CT landmarks, including vessels and nerves, will 
be considered as the clinical target volume. Moreover, in contrast to the level defi-
nition, the carotid artery and jugular veins are included into the CTV The cranial 
border of region 2 is the most cranial CT slice on which vertebra C-I is still visible; 
this is in agreement with the level definition of the Memorial Sloan-Kettering Croup. 
Since the flow of the major lymph nodal chain (jugular chain) is almost perpendic-
ular to the transversal CT scan slices, the caudal- and cranial border of region 2 (level 
II) and region 3 (level III), and of region 3 (level III) and region 4 (level IV), respec-
tively are depicted on one CT slice. In other words, the caudal border of region 2 
(Figure 4-3) is the same as the cranial border of region 3 (Figure 4-4). Furthermore, 
the hyoid body is taken as the border between region 1 (level I) and region 6 (level 
VI), and is considered to correspond to one CT slice. Also some minor modifications 
were made for the dorsal border of regions 2, 3 and 4, and the ventral and dorsal 
border of region 5, because of the different treatment position of the head at the 
time of surgery (rotated head) compared to the position at the time of radiotherapy 
(see Tables 4-2 and 4-3). 
4.2.5 Radiotherapy definition - regions 
Table 4-3 summarizes the definition of the borders of the CT target volume for 
the elective neck with respect to all six regions. As can be seen from this table, if it 
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Table 4-2. Lymph node classification system according to the level definition of the 
Memorial Sloan-Kettering group. (37) The borders of the levels for the surgical 
Target Level I Level II Level III 
Cranial 
Caudal 
Ventral 
Dorsal 
Lateral 
Medial 
Mylohyoid muscle / 
Hyoglossus muscle 
Platysma / 
Hyoid bone 
Mandible 
IA Hyoid bone 
IB Posterior belly 
digastric muscle 
IA Anterior belly 
digastric muscle 
IB Mandible 
IA Not present 
IB Anterior belly 
digastric muscle 
Transverse process 
C-II 
Hyoid bone 
Posterior belly 
digastric muscle 
Posterior border 
sternocleidomastoid 
muscle 
S te rn ocle i do m asto i d 
muscle 
Pharyngeal wall / 
Carotid artery / Deep 
cervical muscles 
Hyoid bone 
Omohyoid muscle 
Sternohyoid muscle / 
Omohyoid muscle 
Posterior border 
sternocleidomastoid 
muscle 
Sternocleidomastoid 
muscle 
Larynx / Pharyngeal wall 
/ Carotid artery / Deep 
cervical muscles 
Figure 4-1. Screen of the module "Definition Target" on CD-i. The CT-tar-
get for the elective neck can be studied by clicking "Contour" and one of 
the colored buttons al the bottom. Every color is associated with a region 
as indicated in the text window at the bottom right. The targel is defined 
by comparing matched anatomy and CT slices using the "slider". 
approach are translated into borders for transversal anatomical sections. 
Target Level IV Level V Level VI 
Cranial Omohyoid muscle Mastoid Hyoid bone 
Caudal Clavicle Clavicle Suprasternal 
notch 
Ventral Sternohyoid muscle Sternocleidomastoid Sternohyoid muscle 
muscle 
Dorsal Sternocleidomastoid Trapezius muscle Vertebra 
muscle 
Lateral Sternocleidomastoid Platysma / Skin Carotid sheel 
muscle 
Medial Thyroid gland / Deep cervical muscles Not present 
Carotid artery 
was not possible to identify a clear landmark, a distance is calculated (cm) in refer-
ence to a well defined and easily recognizable structure on CT (see, for example, 
the dorsal border of region 2 and Table 4-2). Starting with the cranial CT slices will 
facilitate the process of finding the borders of the regions on all CT slices. On every 
CT slice, lateral, medial, ventral, and dorsal borders are defined. A specific border 
can be found by approaching that border from the ipsilateral side, and looking for 
the first structure, mentioned in the list of that border in Table 4-3. 
An audio-visual description of the entire three-dimensional elective target of the 
neck has been implemented on CD-i. For example, select the button "Definition 
Target" in the main menu on the CD-i. Figure 4-1 shows the screen of the target def-
inition module (see also Chapter 6). Selecting a transversal CT, MRI or anatomy slice, 
and "Contour" will show the region definitions on the respective slices. Clicking one 
of the colored buttons will give an audio-visual representation of the region that cor-
responds to the color as indicated in the text window. 
Cranial and caudal borders of the target and critical structures are hard to depict 
on transversal slices. Therefore, frontal and sagittal CT- and MRI images were imple-
mented on CD-i. For example, after selecting "CT", and "Frontal" or "Sagittal", the 
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Table 4~3. Definition of lymph node regions for elective neck irradiation on trans~ 
versal CT slices. The upper parts of regions 2 and 5 coincide: the junctional nodes. 
The caudal parts of regions 4 and 5 also coincide. The borders are defined delineat~ 
Target Region 1 
submental (1 A) and 
submandibular (1 B) 
Cranial 1 A Caudal CT slice 
symphysis mandible 
1B CT slice middle part of 
ramus mandible / Floor 
of mouth muscles 
Caudal 1 A CT slice hyoid body 
1 B CT slice hyoid body 
Ventral 1A Innerside mandible / 
Platysma / Skin 
1 B lnnerside mandible / 
Platysma / Skin 
Dorsal 1 A Floor of mouth 
muscles / Hyoid body 
1 B Digastric muscle / 
Medial pterygoid 
muscle / 1 em ventral 
to vertebra 
Lateral 1 A Line depicted by 
symphysis mandible 
and medial border 
parotid gland / 
Digastric muscle 
1B Innerside mandible / 
Platysma / Skin 
Medial 1 A Not present 
1 B Lateral border IA 
Region 2 
high-jugular 
Cranial CT slice C-I 
CT slice hyoid body 
1/3 of ramus mandible 
/ 2 cm ventral to 
vertebra / Hyoid body 
2 em dorsal to ventral 
border of vertebra 
Medial pterygoid 
muscle / Parotid gland 
/ Sternocleidomastoid 
muscle / Platysma / 
Skin 
Pharyngeal wall / 
medial border carotid 
artery / Deep cervical 
muscles 
Region 3 
mid~jugular 
Caudal CT slice 
hyoid body 
CT slice caudal to 
thyroid cartilage 
Hyoid body / 
Platysma / Skin 
Dorsal border 
vertebral body 
Sternocleidomastoid 
muscle / Platysma / 
Skin 
Larynx / Pharyngeal 
wall / medial border 
carotid artery / Deep 
cervical muscles 
ing the target on the CT slices in a crania-caudal direction. The "/" indicates that the 
border is either one of the structures mentioned, that is the first structure in the list 
found on the CT slice is the border. 
Target 
Cranial 
Caudal 
Ventral 
Dorsal 
Lateral 
Medial 
Region 4 
low-jugular 
CT slice caudal to 
thyroid cartilage 
Cranial CT slice with 
origin sternocleido-
mastoid muscle 
(approximately 2 cm 
cranial to sterno-
clavicular joint) 
Platysma I Skin I 
Sternocleidomastoid 
muscle / Clavicle 
Dorsal border vertebral 
body / Transverse 
process / Rib 
Most lateral part 
sternocleidomastoid 
muscle I Platysma I 
Skin 
Thyroid gland I medial 
border carotid artery / 
Esophagus 
Region 5 
posterior triangle 
Cranial border 
region 2 
Caudal border 
region 4 
Dorsal border 
regions 2, 3 and 4 
1 cm ventral to spinous 
process vertebra / most 
ventral part trapezius 
muscle / lung / ventral 
border rib 
Most ventral part 
trapezius muscle / most 
medial part clavicle / 
Platysma I Skin 
Vertebra / Deep cervical 
muscles 
Region 6 
anterior 
CT slice Hyoid body 
Caudal border 
region 4 
Skin 
Vertebra 
Carotid sheet / 
Thyroid gland 
Not present 
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Figure 4-2. Region 1: borders are in blue-outline on the anatomy slices (left) and in orange (region 
lA) and in red (region 18) colorwash on the CT slices (right). The upper and lower borders of 
region 1 A were on two consecutive slices of the human cadaver. 
Figure 4-3. Region 2: borders are in blue oulline on the anatomy slices (left) and in yellow color-
wash on the CT slices (right). 
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Figure 4-4. Region 3: borders are in blue outline on the anatomy slices (left) and in green color-
wash on the CT slices (right). 
Figure 4-5. Region 4: borders are in blue outline on the anatomy slices (left) and in purple color-
wash on the CT slices (right) . 
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Figure 4-6. Region 5: borders are in blue outline on the anatomy slices (left) and in blue colorwash 
on the CT slices (right). 
contours on all frontal or sagittal CT slices (if any defined for the selected image) can 
be studied on the CD-i. 
In the module "Magnified Target", a summary is given of the target definition. 
Borders are defined on full screen anatomy and CT images. Three levels of each 
region are shown; two represent the cranial and caudal border of that region, and 
an other slice is located in between. 
The description of the outlines of the regions is represented by Figure 4-2 through 
4-6. The borders of each region are shown in a yellow outline on the anatomy 
images (left side of the figures), and in colorwash on the CT slices (right side of the 
figures). The colors correspond to the colors of the regions on CD-i. 
Region 1 is always treated as a single entity. On the other hand it is easier to 
describe this region by splitting it into two sub-regions 1 A and 1 B, like the surgical 
definition of level I. Moreover, both sub-regions correspond to different anatomical 
sites; region 1 A encloses the submental lymph nodes, and region 1 B the sub-
mandibular lymph nodes. For these reasons in Table 4-3 and on CD-i region 1 was 
divided into regions 1 A and 1 B. Due to the position of the head of the human 
cadaver only two consecutive slices represent region lA (Figure 4-2). The borders of 
region 1 A are the mandible, the hyoid bone, the skin (platysma), the floor of mouth 
muscles (the mylohyoid- and the hyoglossus muscle), and the digastric muscle. If the 
digastric muscle can not identified clearly, the line connecting the symphysis 
mandible and the medial border of the parotid gland is used. The borders of region 
1 B (Figure 4-2) are the mandible, the hyoid bone, the skin (platysma), the floor of 
mouth muscles, the medial pterygoid muscle, and the digastric muscle (or the line 
running from the symphysis mandible to the medial border of the parotid gland). If 
the dorsal border can not be identified it will be situated 1 cm ventral to the verte-
bral body. Region 1 corresponds to levels IA and IB without any adjustments. 
The borders of region 2 in Figure 4-3 are delineated by distances from the ven-
tral border of the vertebral bodies (2 cm ventral and dorsal), the medial borders of 
the medial pterygoid muscle and the parotid gland, the skin (platysma), the stern-
ocleidomastoid muscle, the hyoid body, and the pharyngeal wall and deep cervical 
muscles. The distance between the ventral border of the vertebra and one third of 
the ramus mandible is also roughly 2 cm. The cranial border is in agreement with 
the Memorial Sioan-I<ettering level definition. Given the different treatment position 
during radiotherapy compared to surgery (rotation of the head), the dorsal border 
was adjusted. In view of the close relationship of the lymphatics with the carotid 
artery and the jugular vein, these blood vessels were included in the target volume. 
The caudal border is the CT slice showing a major part of the hyoid body. 
Figure 4-4 summarizes the definition of region 3. The borders of this region agree 
with the borders of region 2. The larynx will be a new medial border. The dorsal 
border is the width of the vertebral body (about 2 cm) dorsal to the ventral border 
of the vertebra. The cranial border of region 3 is the caudal border of region 2. The 
caudal border is the CT slice caudal to the thyroid cartilage. 
Figure 4-5 depicts region 4. The borders are the skin (platysma), the sternoclei-
domastoid muscle, the clavicle, the transverse process of the vertebra, the rib, the 
thyroid gland, and the esophagus. The cranial border is the caudal border of region 3. 
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Cranial 
Figure 4-7. Delineation of the elective larget in the neck by three radiation 
oncologists. Regions 1 through 5 were delineated on CT scans, and a 
beam's eye view reconstruction was made. Only minor deviations are seen 
in the beam's eye view images. 
The caudal border ends at the insertion of the sternocleidomastoid muscle on the 
clavicle, which is cranial to the sternoclavicu lar joint. 
The ventral border of region 5 in Figure 4-6 is the dorsal border of regions 2, 3, 
and 4. The cranial and caudal border are the cran ial border of region 2 and the cau-
da l border of region 4, respectively. A cranial adjustment of the dorsal border was 
made, being 1 em ventra ll y to the spinous process of the vertebra. The most cranial 
part of region 5 coincides more or less with region 2. The common area encom-
passes the junctional lymph nodes. The caudal part of this region coincides more or 
less with region 4. The most difficult parts to delineate (and to describe) are the lat-
eral and dorsal borders, because the lymphatics of the posterior neck triangle move 
from cran iall y, the lateral and dorsal part of the neck to caudall y, the medial and 
ventral part of the neck. The dorsal border is a lways ventral to the most ventral part 
of the trapezius muscle, the lung and the ribs. The lateral border is a lways medial to 
the most medial part of the clavicle and the most ventral part of the trapezius mus-
cle. 
4.3 Verification of the three-dimensional target definition 
The CT defined regions are based on the surgical levels as presented by the 
Memoria l Sloan-Kettering Croup, and which have proven to be consistent and valu-
able in clinical practice. As a first test of reproducibility, two independent head and 
neck radiation oncologists and a resident in radiation oncology delineated all 
50 
Elective Irradiation of the Neck 
Supraglottic Larynx 
Figure 4-8 Comparison of conventional portals for a T3NO supraglottic larynx carci-
noma (see Chapter 2) and a beam's eye view reconstruction althe target delineat-
ed on CT slices. Red area: primary tumor and regions 2 and 3, delineated on CT, 
and reconstructed on simulation film (beam's eye view). Solid lines: conventional 
portals as drawn by the different radiation oncologists for a similar tumor. Green 
areas: projection of the parotid and submandibular glands on simulation film . 
regions on CT scans of five different patients. W ith the help of beam's eye view 
images, the CT based portals were compared (Figure 4-7). Only minor differences 
were observed, particularly when comparing these discrepancies to the variations in 
outcome found in the national survey (Figu re 4-8). 
However,. the best test of consistency wou ld be to give any radiation oncologist 
the opportunity to define a three-dimensional NO neck target and compare it with 
the definition as described here. With an interactive medium such as CD-i, this is 
possible and has been implemented . 
In order to define the CT target on the CD-i, one has to choose "Defin ition 
Target" in the main menu (see Figure 4-1). A transversal CT slice is chosen, using the 
"transversal " and Ii next" or IIprevious" buttons. Selecting "Anatomy" wil l show the 
corresponding anatomy sl ice in the image w indow. The border of a level on this 
image can be chosen using Table 4-2. Using the slider, the location of this borcler is 
found on the CT. A structure on the CT sli ce corresponding to th is location is iden-
tified. As mentioned previously this border may be corrected. The newly defined 
borders can finally be compared with the CT target definition given in this chapter. 
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CHAPTER 5 
ELECTIVE NECK IRRADIATION 
CONFORMAL TECHNIQUES 

5 Elective neck irradiation - conformal techniques 
5.1 General 
5.1.1 Beam intensity modifiers 
In elective neck irradiation, the three-dimensional target of the NO neck is a very 
irregular- and large target volume, within an irregular body contour. Depending on 
the site of the primary tumor, air cavities can exist in dose approximation to the tar-
get volume. These aspects make it difficult to obtain a homogeneous dose distribu-
tion in the target volume. Several authors have therefore advocated the use of inten-
sity modulated beams to produce optimal dose distributions in these circumstances 
(16). Calculation of the required beam intensity profiles is possible using a variety of 
methods (e.g. feasibility search, simulated annealing, filtered back-projection) and 
constraints (e.g. prescription dose, tumor control probability, uncomplicated con-
trol) (5,17,48,49). In general, these procedures aim at optimization of the target 
dose homogeneity and, at the same time, sparing of the surrounding critical struc-
tures. In the three-dimensional planning system used in Rotterdam (i.e. CADPLAN), 
target dose optimization is implemented (so called "target compensation"). Sparing 
of critical structures is possible but it depends heavily on the expert input of the 
dosimetrist and/or physicist. A further constraint is that the dose homogeneity with-
in the target should be better than 20% before starting the optimization program. 
The target compensation procedure has extensively been described by Uls0 et al. 
(43,44). The resulting intensity profiles usually exhibit large gradients. By smoothing 
the profiles, however, an acceptable beam intensity modifier is produced. By means 
of a milling machine, it is then possible to construct such a beam intensity modifier 
(i.e. tissue compensator), or one could reproduce the beam intensity profiles with a 
dynamic multi leaf collimator. 
5.1.2 Margins 
The extra margin around the CTV to correct for patient positioning errors was 5 
mm. This new volume (i.e. PTV) extends outside the body contour. In order to cal-
culate a beam intensity modifier, the target compensation procedure requires that 
the PTV lies within the body contour (actually the build-up area of a beam). This 
adjusted PTV (PTV-a) was used for the calculation of dose-distributions, DVH and 
TCP values of the target, and the original PTV to define the portals. For further clar-
ification, the slide show "Materials and Methods" in the "Introduction" submenu of 
the CD-i should be consulted. However, the dose to normal tissues may be under-
estimated as, ariSing from patient setup variations during multiple fractions, a larger 
part of the critical structures will be irradiated. Consequently, a second approxima-
tion was used to better estimate the dose to critical structures. Patient positioning 
errors during a course of radiotherapy were incorporated in the dose calculation 
algorithm in CADPLAN by convolution of the photon kernel with a gaussian distri-
bution. A sigma of 3 mrn was used, this being the standard deviation for positioning 
errors in head and neck cancer observed in a prospective study performed in the 
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Figure 5-1 Clinical target volume (CTV) 01 an early stage nasopharyngeal cancer (left) and of 
a supraglottic larynx cancer (right) at the level 01 the parotid glands. The CTV is oullined in 
red-, the parotid glands in green- and the spinal cord in blue colorwash. 
DHCC/UHR (18). As a result, a margin around the CTV is not necessary and treat-
ment plans can be evaluated with respect to the CTV However, this approximation 
assumes an infinite number of fractions. In o rder to better judge sparing of the sali-
vary gla nds by conformal radiotherapy, both approximations were studied to calcu-
late dose distributions. 
5.1.3 Comparison of treatment plans 
The best way to evaluate treatment pla ns is to inspect each individual dose dis-
tribution in mu ltiple planes. However, this may be cumbersome, if not practica lly 
impossible, if the whole three-dimensional target includ ing the critical organs fo r 
several treatment plans is to be studied. Several procedures are available, however, 
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Figure 5-2. Screen of the "Radiation Therapy" module on CD-i. The 
image window shows a selected CT slice with the outlined clinical 
target volume of an early stage nasopharynx cancer (red) and the 
critical structures (green, see also Figure 5-1) 
to facilitate this process. In general these methods reduce the information of the 
three-dimensional dose distribution to two- and even to one dimension. For exam-
ple, cumulative dose-volume histograms (DVH) are two-dimensional representa-
tions. They tell what percentage of the target volume or volume of interest will 
receive at least a certain dose (or more than a certain dose), but information regard-
ing the location is lost. Using bio-physical models it is even possible to give one-
dimensional representations; i.e. figures of merit that estimate tumor control prob-
ability (TCP) and/or normal tissue complication probability (NTCP). Although allow-
ing for reasonable approximations, the bio-physical models are imperfect and the 
comparison of treatment plans currently has still many limitations. The models used 
in order to calculate TCP and NTCP values, have been presented by Coitein and 
Kutcher (14,22). 
5.2 Three-dimensional treatment planning of the elective neck 
5.2.1 Contouring 
To demonstrate the benefit of conformal radiotherapy in elective neck irradiation, 
two primary tumor sites were chosen: an early stage cancer of the nasopharynx (NP) 
and of the supraglottic larynx (SL). The regions for the NP to be treated were regions 
2 through 5. For the SL, we elected to irradiate regions 2 and 3 in case of elective 
neck irradiation. Firstly, the CT slices from the second human cadaver were for-
warded to CAD PLAN. Body contours (automatically), and the contours of the two 
primary tumor sites (with a margin for subclinical disease, CTV-I), the elective neck 
regions (CTV-II), the PTV and PTV-a and the contours of the critical structures 
(parotid glands, submandibular glands, spinal cord) were delineated on every CT 
slice. Figure 5-1 depicts the CTV of both primary tumor sites on CT at the level of 
the parotid glands. 
On the CD-i, the entire three-dimensional CTV of both primary tumors can be 
inspected. For example choose "Radiation Therapy" in the main menu (Figure 5-2). 
After selecting the primary tumor and "Contour", the target and critical structures 
can be seen and studied on every CT- and MRI slice as well as on the anatomical 
images by using the navigation buttons. 
5.2.2 Treatment techniques 
Some constraints were imposed upon the conformal radiotherapy technique. 
Firstly: theoretically the same or better loco-regional control rates should be 
obtained compared to conventional techniques, with at the same time sparing of 
the major salivary glands as much as possible. Secondly: care was taken not to sur-
pass the tolerance dose of the spinal cord when increasing the dose to the primary 
tumor. Thirdly: the technique should be feasible in a regular (busy) radiotherapy 
department. 
The prescribed dose was 46 Cy at the mean isodose percentage of the target vol-
ume. In accordance with ICRU-50 recommendations, the 95% isodose curves (sur-
face) should encompass the whole target volume and the maximum dose within the 
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Six-Field CRT 
Nasopharynx 
Figure 5-3 .. Typical field arrangement for the described conformal radiotherapy 
of the nasopharynx and the supraglottic larynx. Red area: typical clinical target 
volume, red line: planning target volume, green area: parotid glands, blue area: 
cord. Six field with beam's eye view blocks are outlined. 
target should be less than 107% of the prescription dose. Subsequently a six-field 
conformal radiotherapy treatment plan with one isocenter was developed using 6 
MV photons generated in a KD-2 linear accelerator (Siemens) for both primary 
tumor sites. Figure 5-3 shows schematica ll y the fie ld arrangement which was essen-
tially the same for both primary tumors (i.e. nasopharynx and supraglottic larynx). 
Before starting the compensator program the treatment plan was optimized in such 
a way that the dose to the parotid glands was minimized and that the 80% isodose 
curve/su rface encompassed the planning target volume. This was achieved by 
adjusting the beam positions with the beam's eye view option of CADPLAN, by 
sh ielding part of the sa livary glands an spinal cord in every beam with beam's eye 
view blocks, and by varying the beam weights. For example, for the oblique beams 
one parotid gland will not be irradiated at all. As a consequence a lso part of the tar-
get volume wi ll not be irradiated, but this is compensated for by the other beams. 
For the evaluation of conformal radiotherapy, three conventiona l techn iques 
were planned. One involved portals drawn by the radiation oncologist directly on 
simulation films without knowledge of a three-dimensional target definition. These 
portals are comparable to the national survey study (see also Chapter 4). The sec-
ond conventional technique is sim ilar to first one, but it uses the three-dimensional 
CT definition. With the beam's eye view option of the planning system, customized 
blocks were placed around the target. In the third technique, the second technique 
was optimized, i.e. the lateral beams were rotated in such a way that the proximal 
shoulder of the human cadaver was outside the radiation fields. Dose prescription 
was the same as for the conformal radiotherapy technique. On CD -i, all beam's eye 
view images can be studied. For example to inspect the beams of the conformal 
radiotherapy technique of the NP choose "Beams Eye View" in the main menu of 
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Figure 5-4. Screen of the "Beam's Eye View" module on CD-i. The "eye of the observer' 
is in Ihe focus of the chosen beam looking in the beam direction 10 the patient. The red 
area of the image represents the target of the nasopharynx cancer or the supraglottic lar-
ynx cancer, the blue area the body oulline of the patient, the two shades of green the crit-
ical structures (salivary glands light green, spinal cord dark green). The areas with red 
and green squares indicate an overlap of target and critical structures seen from this 
direction. The yellow hatched area is the shielded part of the beam. 
the CD-i (Figure 5-4). After selecting the NP, every beam can be seen wi th the beam 
selector buttons. 
5.2.3 Dose distributions 
For both the NP and SL cancer, dose distributions were calculated for all treat-
ment techniques on all transversa l CT slices. Dose distributions were reconstructed 
with AVS for frontal and sagittal CT (and MRI) slices (see also Chapter 4). DVHs, 
TCPs and NTCPs were calculated for the PTV-a, CTV, sal ivary glands and spinal cord. 
The DVH and TCP of the primary tumors were calculated w ith and without convo-
lution of the photon kernel for respectively the PTV-a and CTV 
In Figures 5-5 and 5-6 dose distributions of the optimized conventional tech-
nique using beam's eye view blocks and the conformal radiotherapy technique are 
compared at the level of the parotid and submandibular glands for both primary 
tu mor sites. 
Dose distributions of the conformal radiotherapy technique appear superior to 
the conventional technique. This was confirmed by comparing the DVHs (Figure 5-
7) and the ca lculated TCPs and NTCPs (Tables 5-1 and 5-2) using both treatment 
techn iques for the target volume and the parotid glands. To a somewhat lesser 
extent, sparing of the submandibular glands seems also better feas ible wi th the con-
formal radiotherapy technique. The gain in NTCP value is, however, small. 
A ful l presentation of the treatment techniques is provided on the CD-i. Dose dis-
tr ibutions are presented on transversa l CT and MRI as well on the anatomica l slices. 
For example, in order to compare treatment techniques of the SL cancer choose, 
from the main menu "Radiation Therapy" (Figure 5-8) 
Select the SL cancer and "Show Dose". After choosing "Compare" several treat-
ment techn iques can now be selected and the dose distributions of these techniques 
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Figure 5-6. Comparison of dose distributions of the optimized conventional radiotherapy- (panels 
A-C) and the conformal radiotherapy technique (panels D-F) for an early stage nasopharynx can-
cer. Transversal slices are at the level of the parotid glands (panels A, D) and the submandibular 
glands (panels B, E). Frontal slices are at the level of the parotid glands (panels C, F) . 
Figure 5-7. Comparison of dose distributions of the optimized conventional radiotherapy- (panels 
A-C) and the conformal radiotherapy technique (panels O-F) for an early stage supraglottic larynx 
cancer. Transversal slices are at the level of the parotid glands (panels A, 0) and the sub-
mandibular glands (panels 8 , E). Frontal slices are at the level of the parotid glands (panels C, F). 
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Figure 5-6. Dose volume histograms of the planning target volume (top) and right parotid gland 
(bottom) of an early stage supraglottic larynx cancer (left) and nasopharynx cancer (right). 
Solid line: optimized conventional technique, dashed line: six-field conformallechnique. 
can be compared to each other with the "Step" function. Selecting "Evaluate", the 
same can be done for the DVH-, TCP- and NTCP values of the different treatment 
techniques. 
Table 5-1. Tumor control probability (TCP) and normal tissue complication 
probability (NTCP) of the supraglottic laryngeal cancer for the different tech-
niques (see text), RP and LP: right and left parotid gland respectively. RS and 
LS: right and left submandibular gland respectively. SC: spinal cord. CRT: 
conformal radiotherapy-
Technique TCPI'Yo) NTCP ['Yo) 
PTV-a CTV RP LP RS LS SC 
Simulation X-ray 58.9 88.4 29.5 40.6 50.7 56.0 2.2 
beam's eye view 82.0 90.2 34.1 38.9 49.8 53.1 2.2 
blocks 
beam's eye view 84.6 84.6 25.8 22.7 49.9 53.4 2.4 
blocks optimized 
CRT 91.5 96.2 1.9 8.6 37.2 31 . .1 0.3 
CRT cr = 3 mm 94.5 97.3 9.1 18.6 38.7 33.1 0.4 
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Figure 5-8. Screen of the "Rad iation Therapy" module on CD-l. The 
image window shows a selected CT slice with the dose distribution 
belonging to the conformal radiotherapy technique of an early stage 
supraglottic larynx cancer. 
From the figures, the tables, and by consul ting the CD-i, it is appa rent that theo-
retically conformal radiothe rapy is able to spare the parotid and to a lesser extent 
the submandibula r glands better than when using the conventional techniques with 
equal or even improved coverage of the target volume. Unfo rtunately, this goa l is 
reached by smearing out the dose outside the target volume at the cost of more 
dose to oral cavity. Whether this conformal radiotherapy technique will produce less 
xerostomia can only be tested and objectivated in preferably a randomized trial, 
using also su bjective scoring listings ("degree xerostomia") and sa liva production 
measurements as parameter functions. These types of studies will in fact be initiat-
ed in the near futu re, but this subj ect is, however, beyond the scope of this thesis. 
Table 5-2. Tumor control probabi lity (TC?) and normal tissue complication 
probability (NTC?) of the nasopharyngeal cancer for the different techn iques 
(see text and legend Table 5-1). 
Technique TCP 1%1 NTCP 1%1 
PTV-a CTV RP LP RS LS 5C 
Simulation X-ray 54.1 85 .1 44.8 48.9 67.6 71.9 5.1 
beam's eye view 88. 9 93.9 42.2 47.3 58 .1 60.9 4.7 
blocks 
beam's eye view 88 .2 93.5 41.7 47.9 50.7 54.0 4.7 
blocks optimized 
CRT 92.0 96.6 19.9 35.3 37.4 42.2 1.2 
CRT (J ~ 3 mm 91.3 96. 7 19.1 33.9 37.1 41.5 1.2 
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CHAPTER 6 
VISUAL JUSTIFICATION 
/ 
6 Visual justification 
6.1 CD-i introduction 
A three-dimensional CT definition of the target of the neck was presented in 
Chapter 4. Two primary cancers in the head and neck without detectable lymph 
nodes were illustrated: a T2NO nasopharynx cancer and a T3NO supraglottic larynx 
cancer. Using the CT target definition of the elective neck in Chapter 4, a conformal 
radiotherapy technique was developed for the combined primary tumor target and 
the neck target, demonstrating the potential benefit of conformal radiotherapy (see 
Chapter 5). The CT target definition of the elective neck and the procedures to 
arrive at this definition have been implemented in the modules "Definition Target" 
and "Magnified Target" on the CD-i. The conformal technique developed in 
Chapter 5 and the comparison with conventional techniques have been imple-
mented in two modules on the CD-i. The "Beam's Eye View" module shows the 
beam arrangements of the conventional and conformal techniques. In the 
"Radiation Therapy" module, the dose distributions and DVH data belonging to the 
conventional and conformal techniques are compared. Slide shows, clarificating 
how these data were obtained and why this study was performed, were added. Also 
an introductory slide show was implemented showing the path from patient entry 
to actual treatment on a MM50 racetrack microtron in the DHCC/UHR. The rea-
sons for the development of the CD-i can be summarized as follows. 
The CT definition of the three-dimensional target for elective neck irradiation 
results in huge amount of images. For verification purposes and for educational rea-
sons it is necessary to show the entire CT definition of the regions in the neck on all 
(appropriate) images. An interactive medium like CD-i is perfectly suitable for this 
purpose. One of the main goals for the design of the CT definition module on the 
CD-i was to give the user the opportunity to reconstruct the CT definition proce-
dure. This will provide him/her with the tools to create his/her own CT definition 
and then e.g. verify this with the available anatomical data. This is one of the best 
justifications of the appropriateness of the presented CT definition in Chapter 4. 
When delineating the regions according to the definition in Chapter 4, it can some-
times still be difficult to find the exact borders. However, the radiation oncologist 
can search for a matching image and this way the CD-i provides helpful information 
to arrive at the precise CT definition. The interface of the CD-i should therefore 
allow the user rapidly to select a certain image and show the region of interest. In 
general, this module was also constructed as a teaching tool. 
One way to evaluate the benefit of conformal radiotherapy for the elective neck 
irradiation over conventional radiotherapy techniques is by comparing dose-distrib-
utions of different plans side by side (15). In case of conformal radiotherapy, this 
should be done for the entire three-dimensional target volume, including frontal 
and sagittal slices. The objective for the CD-i interface was to implement an easy 
procedure to do so. Similarly it should be possible to compare DVH curves of all the 
treatment plans. 
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6.2 Content and design of the CD-i 
The design of the interface will be clear by studying the flowchart of the program. 
The flowchart itself is divided into eight parts (Flowchart 6-1 through 6-8). The 
explanation of the symbols used in the flowcharts is outlined in Table 6-1. 
Table 6-1. Explanation of the symbols used in the flowcharts. 
I 
6.2.1 Menu 
Symbol Explanation 
( 81,,1 ) 
Slide Show 
Multiple 
Choices 
Stored 
Images 
Program Action 
Start/Stop CO-i program 
Visible interface on the 
television set 
Slide show 
Action that user performs 
(decision of the program) 
Group of buttons that will 
iniatiate the same kind of 
program action 
I mage library on CD-i 
Flow of program depends on 
state of program, c.q. buttons 
Action that program performs 
Jump to other (part aD flowchart 
Flowchart 6-1 shows the menus of the CD-i. When starting the program, an intro-
ductory slide shown is automatically started, showing the intake and treatment of a 
patient by radiotherapy in general and on the MM50 in particular. By clicking a 
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Main Menu 
Flowchart 6-1. Module showing the main menu and the "Introduction" menu. For explanation see text. 
mouse button, the slide show can be stopped. After this slide show the main menu 
shows up (Figure 6-1). 
Six options are possible. The "Definition Target" button gives access to a module 
to study the three-dimensional CT target for elective neck irradiation as derived in 
Chapter 4. The "Magnified Target" button opens a menu that summarizes the target 
definition on a few enlarged images. The buttons "Beam's Eye View" and "Radiation 
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Figure 6-1. The main menu with five choices and an exit button. 
Therapy" w ill bring up modules respectively to study beam positioning and dose 
distributions/DVH curves for elective neck irradiation of an early stage NP and SL 
cancer treated by conventional and conformal radiation techniques, as developed 
in Chapter 5. The "Exit" button starts a slide show with acknowledgments before the 
program stops. The " Introduction" button displays a submenu with another three 
options (Figure 6-2). 
Two of them will d isplay slide shows. "Rationale" explains why th is study was per-
formed and shows the underlying basis of the three-dimensional CT definition for 
elect ive neck irradiation. "Methods & Materials" shows how the data for the other 
modules were obtained. " Exit" d isplays the main menu again. 
6.2.2 Definition target 
This module gives the three-dimensional target definition of the elective neck on 
CT-, MRI- and anatomical slices (see Chapter 4). The procedure to arr ive at the def-
inition has also been implemented, allowing the user to create his "own" defin ition 
and compare it wi th the one given. 
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RATIONAlE. 
Figure 6-2. The "Introduction" menu, thaI gives access to two 
slide shows: ~Rationale" and "Materials & Methods". 
Figure 6-3. Opening screen of the "Definition Target" menu. 
After push ing the " Definition Target" button the screen of Figure 6-3 is seen. The 
image w indow on the left may show transversal CT-, MRI slices or anatomical sec-
tions, or frontal or sagi ttal CT- or MRI slices. The panel on the right al lows the user 
to choose an image. The panel at the bottom shows the contour buttons that give a 
audiovisual description or colorwash representation of the contours. The slider 
down-right is a crucial part of this interface as wi ll be seen. 
Flowcharts 6-2 and 6-3 explain all possible actions. After startup, a sagittal CT 
slice in the midline is shown. The matched MRI slice is also automatically loaded 
into memory (there are no sagi ttal anatomical sections) and can be seen by pushing 
the sl ider to the right. By holding the slider with the mouse, the slider can continu-
ously be moved ; depending on the posi tion of the sl ider, CT- and MRI images are 
mixed and seen in the image w indow (F lowchart 6-2). If sagitta l or fronta l sli ces are 
chosen, only CT- and MRI images can be mixed. The anatomy icon/button is in that 
case disabled. If a transversal image is chosen, the CT-, MRI- and anatomy icons/but-
tons are al l active. If one pushes a CT-, MRI- or anatomy button, the cursor is con-
fined to the CT-, MRI- and anatomy button area. As ind icated in the message box 
below the sl ider, by using one of the other two buttons combinations of images as 
outlined in Table 6-2 should be selected for comparison purposes (Flowchart 6-3). 
Table 6 M 2. Possible and preferred combinations of images that can be COI11 -
pared in the "Target Definition" module. 
Orientation Slider 
Left Right 
Transversal CT MRI 
Transversal CT anatomy 
Transversal MRI anatomy 
Sagittal CT MRI 
Frontal CT MRI 
One can advance one slice forward or backward by pushing respectively the "+" 
or "- " button. The actual position is indicated by the line in the overview box above 
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3 
,-----.(11 
Seleel 
CT,MRI 
or Anatomy 
~------~~ 12 
Select 
Frontal, Sagittal 
or Transversal 
Present? 
Flowchart 6-2. The "Definition Target" module. Branches 11 and 12 refer to Flowchart 6-3. 
these buttons (and by the number of the slice in between these buttons). One 
advances fast forward or backward by clicking in the overview box, roughly at the 
desired location (Flowchart 6-2). By pushing the transversal-, frontal- or sagittal icons 
slices can be chosen in other orientations. Depending on the actual orientation, the 
icon/button belonging to this orientation is disabled. If, for instance, a sagittal slice 
is shown, the sagittal icon/button is disabled. Then pushing the transversal button 
will confine the cursor to the image area. The cursor itself changes into a horizontal 
line. The user may now choose in the sagittal image a transversal image at a partic-
ularly anatomical structure just by clicking the mouse at that spot. For the CT- and 
MRI images, all transitions are possible. If an anatomical image is chosen, visible or 
not, all the icons/buttons are disabled; only transversal images are implemented 
(Flowchart 6-3). The contour button acts as a toggle. If the button is active, contours 
will be shown on the selected image if any are defined on it. The contours will stay 
visible regardless any other action in this module, even if one temporarily exits the 
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module. Every region (region 1A, 1 B, 2, 3, 4, and 5) has its own color as indicated 
by the colored buttons below the contour toggle. As explained in Chapter 4, region 
1 has been split in two sub.regions (1 A and 1 B) purely to give an easier prescription 
to delineate region 1. When a region button is pushed and that region is present in 
the selected image an audiovisual description of the borders is given. During this 
time in the message box the name (number) of the region is shown (Flowchart 6·2). 
The "Exit" button will bring back the main menu. 
The creation a target definition can be summarized as follows (see also Chapter 
4). The borders of a particular surgical level, i.e. anatomical structures, are outlined 
on the anatomy slices. With the slider corresponding borders are located on the CT 
slices. Often reproducible easy recognizable structures, corresponding to these bor· 
ders, can not be found on the CT slices. New structures are then chosen on the CT 
slices. Some adjustments may also be needed as explained in Chapter 5. 
11 r---,---------------,----------------, 
----------------rl~·~ 
Yo, 
Flowchart 6-3. Module belonging to Flowcharts to change to a transversal-, sagittal-, or 
frontal slice (upper part, 11), and to change to an anatomy-, MRI-, or CT image (lower 
part, 12). Branches 3 and 3a refer to Flowchart 6-2. 
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Figure 6-4. Opening screen of the "Magnified Target" menu. 
6.2.3 Magnified target 
The "Magnified Target" module is a summary of the "Definition Target" module. 
This module a llows for the study of the target volume and the procedure of the def-
inition more precisely on a few slices . For every region, full screen CT- and anato-
my images are implemented at three different "levels". The "levels" are: e ither the 
images belonging to the cra nial border of the region, or the images belonging to the 
Flowchart 6-4. The "Magnified Target" module. 
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caudal border; and finally, an image "level" in between. For region l A, the "level" 
in between is missing due to the position of the head of the specimen (see Figure 
6-4). The borders of the regions on these anatomy images are delineated in a yel-
low outline, whereas the target volumes on these CT slices are given in colorwash. 
The colors correspond to the colors of the regions in the "Definition Target" mod-
ule. They also match the colors of the buttons at the bottom of the "Magnified 
Target" screen (Figure 6-4). Flowchart 6-4 describes the program flow. 
After pushing the "Magnified Target" button in the main menu, Figure 6-4 shows 
up. In the image window at the top-left a sagittal CT sli ce is seen. By clicking on one 
of the colored region buttons a specific region (Region 1 a,b-5) may be chosen. The 
image window is updated with an image on which the cranial and caudal borders 
of the chosen region are indicated by lines. There is also a line in between. Also, the 
three buttons to the right of the image window are updated. They correspond to the 
lines (" levels"). By clicking on a button the CT slice belonging to that level is shown 
full screen. By clicking once somewhere on the screen, the corresponding anatomy 
image is seen full size. Clicking randomly again will bring the "Magnified Target" 
screen back. 
Pushing the "Exit" button wil l display the main menu screen. 
6.2.4 Beam's eye view 
Figure 6-5 shows the screen after pushing the "Beam's Eye View" button. The 
flow of the program is illustrated in Flowchart 6-5. 
This module shows the portals of all the treatment techniques discussed in 
Chapter 5. At the left side of the screen is the beam's eye view window. By pushing 
the nasopharynx or supraglottic larynx button at the top right, the primary tumor site 
can be chosen. 
By pushing one of the numbered "technique" buttons, a particular technique 
may be chosen. Technique 1 consists of lateral parallel opposed portals, w ith or 
without an abutted anterior portal, as conventionally delineated by the radiation 
oncologist on a simulation film. Technique 2 consists of the same portals as tech-
Figure 6-5. Opening screen of the "Beam's Eye View" menu. 
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Simulation Film 
BEV blocks 
BEV blocks optimized 
Conformal Six-Filed 
Flowchart 6-5. The "Beam's Eye View" module. 
nique 1, but the target (using the target definition of Chapter 4) has been delineat-
ed on CT slices, and then beam's eye view, customized blocks were made. 
Technique 2 has also been optimized to give technique 3. Portals were rotated to 
avoid the homo-lateral shoulder. Technique 4 is a six-field conformal technique (see 
Chapter 5). A short description of these techniques is given in the message box 
down right. The little bars in the beam setup window at the right side of the screen 
represent the beams belonging to the chosen technique. By clicking on such a bar, 
the beam's eye view of that beam is seen in the beam's eye view window. 
The "Exit" button will bring back the main menu. 
6.2.5 Radiation therapy 
Clicking on the "Radiation Therapy" button enables the user to evaluate and 
compare the treatment techniques of Chapter 5. All possible actions are shown in 
Flowcharts 6-6, 6-7 and 6-8. The interface looks much alike the interface of the 
"Definition Target" module (Figure 6-6). The image area on the left shows besides 
the CT-, MRI- and anatomical images, DVH curves and TCP- and NTCP values to 
evaluate the plans. The navigation buttons to choose images act the same way as in 
the "Definition Target" module. One can choose transversal CT-, MRI- or anatomi-
cal slices, or frontal or sagittal CT- or MRI slices with the respective buttons, but com-
parison of the slices is not possible (Flowchart 6-7). Again there are a contour but-
ton (toggle), an advance forward and backward button, and a fast forward-backward 
option as in the "Definition Target" module, and a nasopharynx and supraglottic lar-
ynx button that work in the same way as in the "Beam's Eye View" module. When 
the contour button is activated, the CTV (primary tumor and elective neck) of the 
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Figure 6-6. Opening screen of the "Radiation Therapy" menu. 
chosen tumor site is shown in red-, the parotid glands, the submandibular glands 
and the spinal cord in green colorwash (Flowchart 6-6). There are now five tech-
nique buttons. The fifth technique is the same conformal radi otherapy technique as 
6 
Radiation 
Therapy screen 
r--~ 21 
Select 
CT, MRI 
or Anatomy 
1-----~ 22 
Select 
fronlal, Sagittal 
Of Transversal 
31 
Compare, OVH 
Dose dlstributulons r-----r=====:::;.J--~ 
Flowchart 6-6. The "Radiation Therapy" module. 
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No -1 N,,"'~ 
22 
y,,~ Selecl CT H:0 image 
No 
N, I 
-I Select Image H:0 Same kind 
y" 
_I 5.1." Ao""my 
Image H:0 
Flowchart 6-7. Module belonging to Flowchart 6-6 to change to an anatomy-, MRI- , or CT image (upper 
part , 21), and to change to a transversal-, sagittal-, or frontal sUce (lower part, 22). Branches 6 and 6a refer 
to Flowchart 6-6. 
78 
Figure 6-7. Compare and evaluate mode of the "Radiation Therapy" menu. 
Techniques 1 (simulation film) and 4 (conformal six-field) of an early stage 
supraglottic laryngeal cancer are compared. The DVH curve and NTCP value 
of the left parotid gland of technique 4 are shown. 
shown by using button 4 (see also Chapter 6.2.4), but is calculated differently (for 
explanation, see Chapter 5). 
Dose distributions are shown by clicking on the "Show/Hide Dose" button, which 
like the contour button, acts as a toggle. When this button is activated isodose 
curves representing 65%, 75%, 85% and 95% of the prescribed dose of the select-
ed treatment plan are seen (Flowchart 6-8). 
Special attention has been given to comparing treatment plans as illustrated in 
Flowchart 6-8. By clicking on the "Compare" button, which is also an on/off toggle, 
the program will enter a compare mode. The "Step" button is activated and it is then 
possible to select several or all treatment plans. By clicking the "Step" button, the 
dose distributions of the selected treatment plans are sequentially seen in the image 
window. 
00 
>+--{32 
011 Off 
do ~I ShowDVH ~ 
1--.... < Evaluate? ::: .. --{ 32 
011 
33 }-.... < 
Flowchart 6-8. Module belonging to Flowchart 6-6 to show or hide dose distributions and DVHs, and to 
enter compare mode. In compare mode, dose distributions or DVHs of different treatment techniques can 
successively be studied by pushing only one button. Branches 6 and 6a refer to Flowchart 6-6. 
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Any shift of the isodose curves is easily seen without having to "remember" the 
precise location of these curves when comparing plans side by side. By clicking the 
"Evaluate" button, any image of the selected treatment plan, with or without dose 
distribution/contours, is replaced by the DVH curve, and TCP- and NTCP values of 
a volume of interest of the selected treatment plan. The volumes of interest are the 
CT\I, the PTV, the left and right parotid glands, the left and right submandibular 
glands and of the spinal cord. The buttons in the image window below the DVH 
curvets) allow to choose a single volume of interest, or all together. Again in the 
compare mode the DVH curves, and TCP- and NTCP values of the chosen treat-
ment plans may be sequentially studied (see Figure 6-7). 
The "Exit" button will bring back the main menu. 
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Local tumor control in radiation therapy of cancers in the head and neck. 
Background: A retrospective study of 1493 head and neck cancer patients was designed 
to test current radiobiological thinking, postulating the detrimental effect of protracted over-
all treatment times (OTT) and/or split course (SC) regimes in radiation therapy on local tumor 
control. 
Methods: Primary squamous cell carcinomas of the oral cavity (GC), oropharynx (OP), 
hypopharynx (HP), nasopharynx (NP), and larynx radiated with a dose of at least 50 Gy, were 
analyzed. Those patients treated by brachytherapy and/or primary surgery were excluded. A 
detailed analysis of the 997 cancers of the larynx was recently published. This paper focuses 
on the relationship between local tumor control and treatment characteristics for the 496 
tumors originating from the OC, Op, HP, and NP Total doses of radiation ranged from 50 to 
79 Gy, with a mean of 64 Gy. 
Results: A local failure (LF) was observed for 278 patients. Using Cox regression analysis, 
T stage and site were strongly related to LF. Corrected for T stage and with reference to Op, 
tumors in the NP, HP, and OC had a relative LF rate of 0.5, 1.6, and 1.8, respectively. Patients 
treated with continuous course (CC) and higher doses of radiation therapy fared best. No 
association was found with OTT and the use of chemotherapy. 
Conclusions: The results observed for the OC, Op, HP, and NP are in line with the findings 
for the larynx. Analyzing all 1493 patients, for SC regimes lower local control rates were 
observed as opposed to the CC treatment series. Moreover, for the normalized total doses, a 
dose-effect relationship could be est.ablished. This study corroborates that disruption of the 
treatment per se and/or the use of suboptimal total doses of RT are detrimental; it is argued 
that these observations could be of relevance when designing combined modality protocols. 
Keywords: Head and neck, Radiation therapy, Chemotherapy, Local control, Split course, 
Continuous course, Overall treatment time, Dose response 
1 Introduction 
In discussing how to improve cure rates in cancer of the head and neck by radi-
ation therapy (RT), some reports highlight the existence of dose-response relation-
ships and therefore propose the use of high(er) doses of RT (1,2). Others have 
stressed the importance of short overall treatment times (OTT) and/or of abandon-
ing split course radiation therapy (SC-RT) regimes (3-10). Moreover, in the past 
decade, fractionation schedules based on tumor cell kinetics and intrinsic radiosen-
sitivity have been advocated (11-15). Clinical investigators have also proposed to 
use the response of the (primary) tumor to a first series of RT or to a few courses of 
chemotherapy (CHT) as a predictor for radiocurability (16-19). The validity of some 
of these treatment approaches is, however, much debated because of potential 
accelerated repopulation of residual tumor cells during the (rest) period after the first 
(series of) RT or CHT courses (4,11,20-23). 
Over many years, the Rotterdam head and neck Cooperative Croup (Dr Daniel 
den Hoed Cancer Center/University Hospital Rotterdam-Dijkzigt), used a consistent 
RT policy, that is a SC regime (5). Recently, a detailed analysis was presented on the 
effects of total dose, fractionation, SC and continuous course (CC) RT, and OTT on 
local control in 997 patients with cancer of the larynx treated between 1965 and 
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1985 to a minimum dose of 50 Gy (3). This paper adds to the debate by studying 
similar RT treatment related factors as well as the influence of CHT on local control 
in an additional 496 patients with cancers in the oral cavity (OC), oropharynx (OP), 
hypopharynx (HP), and nasopharynx (NP). Finally, by multivariate Cox regression 
analysis all 1493 patients combined were analyzed. 
2 Materials and Methods 
Between 1965 and 1985,496 patients were treated by RT with a minimum dose 
of 50 Gy for a primary squamous cell carcinoma in the OC, Op, NP, and HP. All 
patients were retrospectively staged according to the UICC (1987)/AJCC (1988) clas-
sification recommendations (24,25). Patient and tumor characteristics are summa-
rized in Tables 1 and 2. Most tumors originated in the OP (36%) and HP (30%), with 
the remaining tumor sites equally divided between NP and oc. Regarding all tumor 
sites combined, 54% had stage 13/T4 and 59% had N+ disease at admission. 
Table 1. Patient and tumor characteristics. NO/+: number of patients with-
ouVwith (clinically) detectable lymph nodes at admission. 
Age, mean (range) 63 years (19-92) 
Sex 
male 367 
female 129 
Site 
Oral Cavity (OC) 86 
Oropharynx (OP) 178 
Nasopharynx (NP) 85 
Hypopharynx (HP) 147 
T stage 
T1 61 
T2 165 
T3 175 
T4 95 
Nodal status 
NO 203 
N+ 293 
2.1 RT techniques 
Patients were treated in supine position. Radiotherapy was given by a linear 
accelerator using, in general, 4 to 8 MV photon energies in combination with high-
energy electrons. Immobilizing head shells were used; after simulation, dose calcu-
lation was performed using computer planning. In the majority of cases, the target 
volume was treated by two lateral opposed fields with matched anterior lower neck 
portals down to the clavicles. Field reduction "off-cord" of the photon portals was 
introduced at 40 Cy. Details of the technique have been presented previously (3,5). 
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Table 2. Patient characteristics - distribution by T stage, nodal status, and site. 
OC: oral cavity; OP: oropharynx; NP: nasopharynx; HP: hypopharynx; n: 
total number of patients; %N+: percentage of patients with (clinically) 
detectable lymph nodes at admission. 
Site 
OC or NP HP Total 
T stage n %N+ n %N+ n %N+ n %N+ n %N+ 
T1 7 57 23 43 9 100 22 50 61 56 
T2 31 32 43 60 38 74 53 38 165 51 
T3 21 62 86 64 15 60 53 70 175 65 
T4 27 52 26 62 23 74 19 74 95 64 
Total 86 48 178 60 85 74 147 56 496 59 
2.2 RT protocol 
During the study period, 88% (437/496) of the patients were irradiated inten-
tionally by a SC-RT regime. In the majority of cases, patients were treated five times 
per week with a conventional fraction size of 2 Gy/day. First, a series of 40 Gy was 
applied; subsequently after a variable split period, in case of a complete or partial 
response to 40 Gy or ineligibility for S (because of patient refusal or poor medical 
condition), a second series of RT was given. In this paper, only primary tumors irra-
diated with a minimum tumor dose of 50 Gy were analyzed; patients treated by 
brachytherapy and/or surgery (5) up front or by 5 for a primary cancer after a first 
series of 40 Gy, were excluded. Surgery for a primary cancer after a dose of 50 Gy 
or more was regarded as treatment for local failure (salvage); these patients were 
included in the present analysis. For node negative (NO) patients, elective irradiation 
of the neck was given in 116 of 202 (57%) patients; for Tl ,2 in 55% and for n,4 in 
60% of the cases. Clinically palpable neck nodes were generally treated by a boost-
er dose of RT; however, in 36 patients the first series of 40 Gy was followed by a 
neck dissection. 
According to running protocols during the study period, RT was frequently com-
bined with chemotherapy (CHT) in case of advanced tumor stages (stage III/IV); that 
is, CHT was given in 37% (44/118) of the Tl ,2N+ patients and in 49% (132/270) of 
the n,4 tumors. In 79 of 189 (42%) patients treated by CHT, the cytotoxic agents 
were given in a neoadjuvant setting; sporadically (n~6), CHT was given after com-
pletion of RT. The majority of the patients (55%; 104/189) received CHT in an inter-
ca!ated fashion in between two series of RT; due to the anticipated norma! tissue 
reactions (e.g., dose limiting severe mucositis), the total RT dose to the primary 
tumor in this group was limited up front to 60 Gy. 
2.3 Data Analysis 
Patient data were abstracted from the charts and coded on a dataform. The fol-
lowing data were collected: patient identification number, date of birth, sex, T and 
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N stage, date of diagnosis, site of disease, grade of differentiation, dates of first and 
last fraction of RT to primary, fraction size di in grays for each different fraction size 
applied in a particular patient series, number of fractions with fraction size di (nfi; 
i index for different sizes), number of fractions per day, split (split period in days of 
at least 7 days after a first series of 40 Gy), total dose to treated neck (node), date 
of end of RT, date of local relapse, date of failure in neck, survival status, date of last 
follow-up and/or date of death. 
From the RT data additional parameters could be derived: Total physical dose in 
grays = 0 = Linfi • di, average fraction size d, sum of squared fraction doses = dO 
= Linfi • dr, normalized total dose (NTD) in grays for a/f3 = 10 and fraction size of 
2 Gy {with NTD = l(a/f3 • 0 + dO) / (a/f3 + 2)]), overall treatment time between 
first and last fraction inclusive (OTT), number of days without RT between first and 
last treatment (NTT). 
The analysis is focused on the relationship between RT characteristics and the risk 
of local relapse, taking the effect of tumor characteristics into account with Cox mul-
tivariate regression analysis (26,27). Details of the data analysis methods have been 
described in the paper on local control and OTT regarding cancer of the larynx (3). 
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Table 3. First type of failure - actuarial probability at 3 years. Cancers 
originating in the oral cavity (OC), oropharynx (OP), nasopharynx (NP), and 
hypopharynx (HP). NED: no evidence of disease; NO: no lymph nodes at 
admission; N+: (clinically) detectable lymph nodes at presentation; LF: local 
failure; RF: regional failure. 262 patients presented with a LF as first type of 
relapse, 97 of which at some point in time also experienced a RF; 238/262 
(910/0) succumbed to disease. 65 patients presented with a RF as first type of 
relapse, 16 of which also experienced a LF at some point in time; 61/65 
(94%) succumbed to disease. 32 patients presented with distant metastasis 
as first type of relapse and succumbed to their disease. 
Dead with 
Alive Dead Local Regional distant 
NED NED failure failure metastasis 
(n) (%) (%) (%) (%) (%) 
All 493 24 9 50 13 5 
Site 
OC 86 17 11 61 9 2 
OP 178 30 8 48 11 3 
NP 85 35 4 30 17 14 
HP 147 17 10 56 14 3 
T stage 
T1/T2 226 30 10 39 15 6 
13/T4 270 18 7 60 11 4 
N stage 
NO 203 30 8 54 6 2 
N+ 293 21 9 48 17 7 
3 Results 
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Figure 1. Patients with tumors in the oral cavity (OC), oropharynx 
(OP), nasopharynx (NP), and hypopharynx (HP), radiated with a min-
imum dose of 50 Gy. Actuarial local relapse-free probability by site. 
3.1 General aspects 
At the date of last follow-up, 420 of 496 (85%) patients had died. Almost all 
patients with disease-related (that is, local, regional, and/or distant) failures 
appeared to have died within the first 3 years. 
Two hundred seventy-eight (56%) patients experienced a local failure (LF); the 
median time to LF was 5 months, with 75% of the LF within 1 year and 95% with-
in 3 years. Of those with a LF, 91% died of disease. Of the 218 patients remaining 
locally controlled, 166 (76%) eventually died; that is, 46% (77/166) after a relapse 
in the neck and/or with distant metastasis and 89 of 166 (54%) because of intercur-
rent events. Table 3 tabulates the actuarial probability of first failure type at 3 years 
for the different tumor sites, T stages and lymph nodal status at admission. From 
Table 3 it is apparent that death due to LF is more frequently seen in OC and HP 
tumors and in the more advanced (T3fT 4) tumor stages in general. In NP, death due 
to distant failures is a prominent feature (Table 3). 
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Figure 2. Patients with tumors in the oral cavity, oropharynx, nasophar-
ynx, and hypopharynx, radiated with a minimum dose of 50 Gy. 
Actuarial local relapse-free probability by T stage. 
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Figures 1 and 2 show the actuarial local relapse~free survival (LRFS) for all tumors 
by site and T stage, respectively; Table 4 depicts the local relapse~free (LRF) and 
overall survival (OS) probabilities. 
Table 4. Actuarial survival probabilities. Cancers originating in oral cavity 
(OC), oropharynx (OP), nasopharynx (NP), and hypopharynx (HP). NO/N+: 
no (clinically) detectable lymph nodes at admission; 3~year LRFS: local 
relapse-free survival at 3 years; 5-year as: overall survival at 5 years; (0/0 ± 
SO): percentage ± standard deviation. 
3~year LRFS 5~year as 
Site T stage NO/N+ Number ('Yo ± SO) ('Yo ± SO) 
OC All stages 86 29 ± 5 17 ± 4 
T1/T2 38 34 ± 9 24 ± 7 
T3/T4 48 25 ± 7 12 ± 4 
OP All stages 178 45 ± 4 28 ± 3 
T1/T2 66 58 ± 6 36 ± 6 
T3/T4 112 34 ± 5 23 ± 4 
NP All stages 85 64 ± 6 40 ± 5 
T1/T2 47 73 ± 7 48 ± 8 
T3/T4 38 52 ± 9 30 ± 8 
HP All stages 147 35 ± 4 15 ± 3 
T1/T2 75 49 ± 6 21 ± 5 
T3/T4 72 18 ± 6 8 ± 3 
All sites All stages 493 42 ± 2 24 ± 2 
T1/T2 226 54 ± 4 32 ± 3 
T3/T4 270 32 ± 3 18 ± 2 
NO 203 43 ± 4 28 ± 3 
N+ 293 42 ± 3 21 ± 2 
3.2 Treatment characteristics 
Table 5 shows the treatment characteristics for the SC-RT group as opposed to the 
patients treated by CC~RT. The SC~RT regime was given in 437 patients (88%), CC 
in 12%. The majority of fraction sizes ranged between 1.7 and 2.4 Gy; fraction sizes 
of 1.5~1.7 Gy were applied in 8% and those between 2.4~3.1 Gy in 10% of the 
cases. A close correspondence was found between the total physical dose and the 
normalized total dose (NTD1 0) (r = 0.96); in less than 20% the difference between 
total physical dose and NTD10 was more than 2 Gy, the maximum difference being 
6 Gy. This difference is much smaller than the variation between patients, implying 
that in a regression analysis it is not possible to discriminate between these variables 
as covariates, that is, they are interchangeable. 
The mean OTT of the SC patients was 76 days (43~ 121) versus 40 days (23~51 
days) for the CC series. The number of days without radiation therapy between the 
first and the last fraction (NTT) for the SC as opposed to the CC was 47 versus 13 
days (Table 5). 
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Table 5. Treatment characteristics. RT: radiation therapy; SD: standard devi-
ation; dose: total physical dose; NTD: normalized total dose (see text); OTT: 
overall treatment time; NTT: no treatment time, that iS'number of days with-
out RT between first and last fraction (see text). CC: continuous course; SC: 
split course. 
Split Continuous 
course RT, course RT, Range 
Mean (SD) Mean (SD) SC + CC 
Number of patients 437 59 
Fractions 33 (4) 27 (4) 17 - 49 
Fraction size (Gy) 2.0 (0.24) 2.3 (0.31) 1.5-3.1 
Dose (Gy) 65 (5) 61 (4) 50 - 80 
NTD (Gy) 65 (5) 62 (5) 49 - 80 
OTT 
Days 76 (15) 40 (6) 
Range 43-121 23-51 23 - 121 
NTT 
Days 47 (15) 13 (3) 
Range 23-167 7-19 7 - 167 
With regard to the patients treated by a combined modality protocol, the mean 
OTT of the RT regime, defined as the time between the first and the last fraction, 
was not significantly different for the patients treated with or without CHT; that is, 
for the RT + CHT group, 75 days (range 42-120 days), for the RT-only group, 
68 days (range 22-120 days). 
No difference in LRFS was observed for the T1,2N+ or for the T3,4NO,+ cate-
gory when comparing patients treated with or without CHT (Figure 3). 
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Figure 3. Patients with advanced cancers (stage III/IV) in the oral cavity, 
oropharynx, nasopharynx, and hypopharynx, treated by RT (minimum dose 
of 50 Gy), with or without chemotherapy. NO/+: patients withouVwith (clinical-
ly) detectable lymph nodes at admission. Actuarial local relapse-free survival 
for patients treated with (-) or without (----) chemotherapy for the T1 ,2 N+ 
(n=118) and T3,4 NO,+ (n=270) categories, respectively. 
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3.3 Prognostic factors 
Local relapse-free (LRF) and overall survival (OS) rates are best in tumors origi-
nating in the NP and Op, followed by tumors of the OC and HP (Table 4). For each 
tumor site, T1,2 tumors fare better than locally advanced tumor stages (13,4). A 
multivariate Cox regression analysis demonstrated the independent effects of T stage 
and site (Table 6). The relative local failure rate (RLFR) of tumors in the nasophar-
ynx, with reference to the oropharynx, was 0.5, in the oral cavity tumors 1.8, and 
in the hypopharyngeal cancers 1.6. Nodal status, age, and sex were, as such, not 
correlated with LF when corrected for T stage and site. 
Table 6. Multivariate Cox regression analysis - local relapse. Cancers in the 
oral cavity (OC), oropharynx (OP), nasopharynx (NP), and hypopharynx 
(HP). RLFR: relative locale failure rate; CI: confidence interval; CC: contin-
uous course radiation therapy regime; SC: split course radiation therapy 
regime; NTD: normalized total dose (see text); OTT: overall treatment time. 
RLFR 
Site (vs OP) 
OC 1.8 
NP 0.5 
HP 1.6 
T stage (vs Tl) 
T2 1.6 
T3 2.6 
T4 3.6 
NTD (+ 1 Gy) 0.97 
OTT (+ 1 day) 0.99 
Split (vs. CC) ·1.31l 
95% CI 
1.3-2.5 
0.3-0.8 
1.2-2.1 
1.0-2.6 
1.6-4.2 
2.2-5.9 
0.95-1.0 
0.98-1.0 
0.91-2.1 
p 
[J.O[JO 
0.000 
0.02 
0.13 
0.13 
The relationship between treatment characteristics (elective treatment of the 
neck, NTD, fraction size, OTT, CHT) and LF was also studied in a multivariate Cox 
regression analysis (not shown) and corrected for T stage and site; except for NTD 
(p~O.02), no significant association between any of these treatment characteristics 
and LF rate was observed (Table 6). Figure 4 (left panel) demonstrates the favorable 
outcome of T1/T2 patients treated by CC-RT, as opposed to the SC group (p~O.04). 
However, the difference in LRFS of the CC- vs SC-RT regime for nIT 4 patients was 
found to be not significant (Figure 4; right panel). 
4 Discussion 
Curability of tumors in the head and neck treated by RT is dependent on patient 
characteristics (e.g., age, sex, Karnofsky status), tumor specifics (e.g., tumor site, his-
tology, differentiation grade, site, T stage, N stage), and treatment parameters (e.g., 
fractionation schedule, SC versus CC regimes, total dose, and OTT). We studied 
some of the prognostic factors retrievable from a large data base consisting of 1493 
96 
T1fT2 tumors T3fT4 tumors 
, -
ee (n=28) 
.8 -
o 0 }.6-
i 4- se {n=198} 
i [ 
~ 
.6 -
4- CC (n_31) 
E \ (n=239) 0 ,- SC (5 .2-
(P=O.04) (N.S.) 
.6- L, ________ , ____ _ 6-
6 3 3 
Years Years 
Figure 4. Patients (n=496) treated between 1965-1985 by split course (SC) or continuous course (CC) 
radiation therapy to a minimum primary tumor dose of 50 Gy for cancers originating in the oral cavity, 
oropharynx, nasopharynx, and hypopharynx. Panels display the local relapse-free probability by treat-
ment regimes, that is split course (SC) versus continuous course (CC) RT, and T stage. 
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patients, treated between 1965 and 1985 by RT (with or without CHT) to a mini-
mum dose of 50 Gy. As there is much concern in the current literature regarding the 
hazard of accelerated repopulation in SC regimes and/or RT schedules with long 
OTTs, and since SC designs are (still) not infrequently used in combined modality 
protocols, we have focused the analysis on this particular issue (6,7,8,9,11,22). 
4.1 Tumors in the oral cavity, oropharynx, hypopharynx, and nasopharynx (n=496) 
Table 4 demonstrates the poor as rates at 5 years for the different tumor sites 
and T stages, varying from 8% for T3,4 hypopharyngeal (HP) tumors to 48% for T1 ,2 
tumors originating in the nasopharynx (NP). The LRFS at 3 years varied between 
18% and 73%. The LRFS is considerably better compared to the as (Table 4), but 
the excess death rate due to a high number of intercurrent deaths compared to the 
age- and sex-matched (Dutch) standard population, is a well-established phenome-
non in cancer of the head and neck (5). 
Corrected for other prognostic factors and relative to the tumors in the orophar-
ynx (OP), cancers of the NP fared best in terms of local control (RLFR 0.5; 
p<O.OOl), whereas tumors of the oral cavity (OC) had a 1.8 (p<O.OO1) and those 
of the HP a 1.6 (p<O.OOl) times higher rate of relapse. Moreover, importantly, for 
a!! tumor sites with increasing dose, a significant decrease in the LF rate was 
observed (NTD; p~0.02). Finally, OTT (p~O.13), nodal status (N+ versus NO; 
p~0.95), and sex (female vs male; p~0.55) were not correlated with LF when cor-
rected for T stage, tumor site, and split (Table 6). 
At the time, RT was frequently combined with CHT for advanced tumor stages; 
overall, similar local control (LC) rates were observed for patients treated with CHT 
(39%; 74/189) as opposed to those treated without CHT (47%; 144/307). Moreover, 
the actuarial LRFS at 5 years showed no difference for the T1 ,2N + and T3,4NO/N + 
patients treated with or without CHT (Figure 3). 
The multidrug CHT regimes used were cis-diaminedichloroplatinum based. In a 
substantial number of reports cisplatin has been shown to be a highly active agent 
in previously untreated patients with locally advanced head and neck cancer and 
may yield response rates up to 80%, with 30-40% of patients achieving a complete 
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Figure 5. Patients (n;;;1493) treated between 1965-1985 by split course (SC) or continuous course (CC) 
radiation therapy to a minimum primary tumor dose of 50 Gy for cancers originating in the oral cavity, 
oropharynx, nasopharynx, hypopharynx and larynx. Panels display the local relapse-free probability by 
treatment regimes (SC vs. CC) and T stage. 
response (28,29). However, the optimistic view on induction CHT has, in recent 
years, been considerably tempered (23). In fact, the outcome of randomized stud-
ies and the metaanalysis by Stell and Rawson even corroborated that the benefit of 
induction CHT is almost negligible (30). From phase II studies, the results obtained 
by concurrent CHT and RT (chemoradiation) seem to be more encouraging; how-
ever, normal tissue sequelae have been of major concern, thereby frequently lead-
ing to the design of studies using lower (suboptimal) doses of RT and/or introducing 
a rest (split) period in the treatment (31). In fact, a randomized study by Sanchiz et 
al. demonstrated that chemoradiation compared to adequate doses of RT alone 
gave similar results (32). In summary, as was recently stated by I<allman, at present, 
there is almost universal recognition that the effectiveness of drugs very strongly 
depends upon the schedule by which they are administered, as well as the intensi-
ty of the modalities used; these schedules should be studied preferably by random-
ized protocol designs (33). 
In the multivariate Cox regression analysis, no significant impact of CHT on the 
LF rate in the patients of our study population could be substantiated. However, the 
different subsets of patients treated with CHT were small, and the study was done 
in a nonrandomized fashion. Moreover, the SC protocol and the combination of 
CHT with suboptimal doses of RT (e.g., 60 Gy for advanced tumor stages) are addi-
tional factors that might have adversely influenced the outcome. 
Although the validity of using initial tumor response to RT as a predictor for either 
failure or control is now questionable, the large majority of our study population 
(88%) were treated consistently at the time by a SC-RT regime (4,20,21). From 
Figure 4 one can appreciate that the CC patients had a better LRFS as compared to 
the SC group. However, this difference in favor of the CC is only significant for the 
early (T1/T2) tumor stages (p~0.04). Moreover, after correction for T stage, nodal 
status, and site the difference between SC and CC for all 496 patients is no longer 
significant (p~0.42), probably due to the small total number of CC patients (n~59) 
(Table 6). Since some of these findings might lack statistical power because of too 
small numbers of patients in the different subsets, in the next section we have ana-
lyzed the influence of split, overall treatment time, and dose on LF for all 1493 head 
98 
and neck cancers, including the patients with cancer of the larynx published in 
detail by van Putten et al. in a recent paper (3). 
4.2 All head and neck tumor sites combined (n = 1493) with special reference to dose-
response and split course irradiation 
As can be seen from Figure 5, patients treated by CC-RT fare (much) better than 
those treated by a SC regime. In particular for the T1/T2 tumors, a significant differ-
ence was found (p < 0.001) (Figure 5, left panel). Due to the treatment philosophy 
at the time, especially in the advanced tumor stages (B/T4), SC-RT was the pre-
ferred treatment; indeed, in the CC-B/T4 category only 55 patients are available 
for analysis and (probably for that reason) the difference between SC versus CC was 
found to be not significant (p~0.82) (Figure 5, right panel). 
In dose-effect relationships the effect of dose on LF is assumed to be a continu-
ous effect in the sense that a higher dose implies more cell kill, and thus a lower LF 
rate. In Figures 6 and 7, the probability of local relapse at 3 years is shown as a func-
tion of normalized treatment dose (NTD) for T1/T2 versus B/T 4 tumor stages, treat-
ed by either CC-RT (Figure 6) or SC-RT (Figure 7). Except for the T1/T2-CC patients, 
the data summarized by both figures generate evidence for the existence of a dose-
response relationship. For example, Figure 7 indicates that a 10 Gy decrease in total 
dose roughly corresponds with an 8% decrease in local control. However, as was 
also previously reported by the group of Parsons et aI., with regard to the T1/T2 
tumors, probably high doses of RT might not be so relevant for small tumors treat-
ed adequately in a CC fashion (Figure 6) (10). 
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Figure 7. Patients with all head and neck tumor sites combined (see also legend 
Figure 6), treated with split course radiation therapy (n=840). Actuarial LF-3 probabil-
ities with standard error bars in subgroups: (e) T3,T4, NTD s 64 Gy (n=200); (f) T3,T4, 
NTD 64-69 Gy (n=136); (g) T3,T4, NTD > 69 Gy (n=96); (h) Tl,T2, NTD ~ 64 Gy 
(n=148); (i) Tl,T2, NTD 64-69 Gy (n=124); and U) Tl ,T2, NTD > 69 Gy (n=136). 
The OTT is strongly correlated with the length of the disruption (~ split duration) 
of the treatment, 50 (not shown) an analysis was performed regarding the effects of 
OTT. However, in a multivariate analysis, no effect could be substantiated. 
5 Summary 
This review has implicit., well-known limitations because of its retrospective 
nature; for example, selection bias during the long-term cohort of the study with 
(many) changes in physicians over time can not be totally excluded. 
Concurrent with radiobiological thinking is the establishment of a dose-response 
relationship. That is, with higher doses of RT fewer local failures were observed, a 
finding which seems to be even more import.ant for the more advanced tumor 
stages, with a higher clonogenic tumor load to be killed. Introduction of a split in 
the treatment also leads to more local failures (if not compensated for by the use of 
higher doses of RT). No difference in local relapse-free survival was observed for 
patients treated with or without chemotherapy. it was concluded that for local con-
trol, the use of optimal high total doses of radiation and the elimination of SC 
regimes are important and can be envisaged to be of relevance when designing 
combined modality protocols, for example, for advanced cancers in the head and 
neck. 
We could not unequivocally demonstrate an effect of OTT. One speculation 
could be that interruption of the treatment per se (split) is an overriding discrete 
effect. 
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Radiation therapy for cancer of the piriform sinus - a failure analysis 
This paper analyzes the results of 109 piriform sinus cancers treated between 19~3 and 
1984 by surgery and/or external beam radiation therapy (EBRT) in a large comprehensive 
cancer center, and in particular tries to redefine the role of EBRT in the management of these 
tumors. At the time the policy was to start with EBRT to a dose of 40 Cy. A good response to 
a first series was to be continued by EBRT (RT-1); in case of poor responding tumors, the pri-
mary and neck were to be operated upon (RT-S). Poor responders unfit for surgery or those 
refusing surgery were also carried to a full course of EBRT (RT-2). The RT-S, RT-1, and RT-2 
actuarial 5-year locoregional relapse-free survival (LR-RFS) and overall survival (aS) were 
60%, 40%, and 20% and 40%, 30%, and 20%, respectively. In a multivariate Cox regression 
analysis the most important prognostic factor appeared to be N stage, with hazard ratios of 
1.16 IN1), 2.2 IN2), and 3.3 IN3). The RT-S treatment group fared best (hazard ratio 0.5). The 
risk of relapse for T3,4 was 1.3 times as high as opposed to T1,2. For stage 1/11 (19/21 treat-
ed by EBRT only), a LR-RFS and as at 5 years of 60% and 40%, respectively, was obselved. 
This analysis supports data for stage III/IV piriform sinus cancers to be treated by surgery com-
bined with EBRT; in stage 1/11 there might be a role for EBRT alone. It is speculated that with 
furlher sophistication in RT-techniques, the locoregional control rates by E13RT alone could 
improve. 
Keywords: Head and neck cancer, Hypopharynx, Piriform sinus, I~adiotherapy, Surgery, 
Conformal radiotherapy. 
1 Introduction 
For cancers of the hypopharynx it seems fair to summarize that patients have a 
grim outlook due to a high incidence of locoregional failure and distant metastasis; 
5-year survival rates generally range from 20% to 40% (1,2). Cancers of the piriform 
sinus constitute the majority of hypopharyngeal tumors and are thought to have the 
best prognosis, particularly when diagnosed at an early stage. Most patients with pir-
iform sinus cancer unfortunately present with locally advanced tumors. Moreover, 
approximately 70%-80% of patients have nodal disease at presentation (3-6). Most 
of the (even recent) oncological literature on the hypopharynx does not discriminate 
between specific subsites, so detailed reports on cancer of the piriform sinus prop-
er are scarce. Therefore, a retrospective analysis of patients with cancer of the piri-
form sinus treated in the Dr. Daniel den Hoed Cancer Center (DDHCC) and 
University Hospital Rotterdam Dijkzigt (UHR-D) was performed. Surgery of the pri-
mary site, with or without EBRT, is generally considered to be the mainstay of the 
treatment. One specific goal of the analysis was to see whether a role for primary 
EBRT with larynx (voice) preservation could be defined for a subset of patients. 
2 Material and Methods 
From January 1973 through December 1984, 161 patients with carcinoma of the 
hypopharynx were treated by the Rotterdam Head and Neck Cooperative Croup. 
The location of the primary tumor was piriform sinus in 130 patients, posterior pha-
ryngeal wall in 22 patients, and postcricoid in 9 cases. We confined our study pop-
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ulation to the piriform sinus cancers, treated over the years consistently by a proto-
col in which the treatment modalities used depended on the response of the pri-
mary cancer to a first series of 40 Cy ("RT-selective" protocol). The censor date was 
January 1,1993. From the 130 piriform sinus cancer patients, 3 were excluded from 
further analysis because of distant metastases at presentation. Another 7 patients 
were excluded because they did not receive radiation therapy (RT) from the start, 
that is, they were, for reasons not evident from the charts, operated on upfronl. Five 
patients were excluded because of histolob'Y other than squamous cell carcinoma. 
The remaining 115 piriform sinus squamous cell carcinomas form the data set of the 
present report. 
All patients were retrospectively restaged according to the classification rules of 
the AJCC-1988/UICC-1987 editions (Table 1) (7,8). For the 115 patients, the mean 
age was 65 (range 30-86)- 93 men, 22 women. Regarding the differentiation grade: 
8 were well-differentiated, 43 moderately differentiated, 47 poorly or undifferenti-
ated and for 11 patients the differentiation grade of the cancers was unknown. 
Table 1. Piriform sinus cancer 1973-1984 DDHCC/UHR-D 
T stage 
N stage T1 T2 T3 T4 Total 
NO 7 14 22 3 46 
N1 1 3 12 6 22 
N2a 2 6 7 16 
N2b 3 5 6 15 
N2c 2 4 8 
N3 3 4 0 8 
Total 17 31 55 12 115 
During the study period the treatment protocol was to start with EBRT to a dose 
of 40 Cy (2 Cy per fraction/5 days per week) to the primary tumor and neck by a 
linear accelerator, using low-energy photons (4-8 MV) and electrons (10 MeV). A 
second course of EBRT (protocol: total dose 30 Gy) was given in case a good 
response of the primary tumor (and neck nodes) to the first series of 40 Cy was 
obtained (RT-1 group; 55 patients). For those tumors considered as poor responders, 
that is, less than partial response, the primary and neck were to be operated upon 
(RT-S group; 26 patients). 
Those patients refusing surgery or found medically unfit for operation after a poor 
response to the first series of 40 Gy, were also given a second course of EBRT (RT-2 
group; 28 patients). Table 2 presents a stratification of the number of patients 
according to the different treatment groups. Apparently, 6 tumors were given a low 
cumulative dose of EBRT (mean dose 34 Gy; range: 21-40 Cy); because of a poor 
general condition the treatment of these patients had to be terminated at low doses 
with a residual tumor mass still in situ ("NOTx": no treatment group) and, subse-
quently, these patients experienced early death (survival range: 1-6 months). These 
6 patients were ultimately excluded from the data set exploring the role of EBRT in 
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control of cancers in the piriform sinus, leaving 109 full-protocol patients to be ana-
lyzed for local control and survival by EBRT alone versus EBRT plus surgery (Table 2). 
Table 2. Piriform sinus cancer 1973-1984 DDHCC/UHR-D 
Choice of Treatment RT-I RT-II RT-S NOTx Total 
Good Response 55 55 
Refusing Surgery 7 7 
Inoperable 21 21 
Poor Response 26 26 
Inadequate Treatment 6 6 
Total 55 28 26 6 115 
In analyzing the 109 cases, the primary tumor appeared to have been irradiated 
with a mean total dose of 65 Cy (range: 50-72 Cy) for the RT-1 group of patients; 
64 Cy (range: 40-70 Cy) for the RT-2 group; and 42 Cy (range: 30-70 Cy) for the 
RT-S group. 
In almost every case (104/109) both sides of the neck were electively irradiated 
by a first series of EBRT. Subsequently, neck nodal disease was treated in the major-
ity of cases by the modality that was used to manage the primary cancer; that is, in 
64 of 83 (77%) cases by EBRT and in 19/83 (23%) of the patients by means of a neck 
dissection for the piriform sinus cancers treated by EBRT only (RT-l/RT-2 groups). In 
contrast, in all patients of the RT-S group presenting with neck nodes, a neck dis-
section was performed. 
Table 3. Piriform sinus cancer 1973-1984 DDHCC!UHR-D 
Cause of Death RT-I RT-II RT-S Total 
Tumor 29 21 9 59 
Intercurrent 12 2 4 18 
Postoperative Complication 3 3 
Second Primary 2 3 
Unknown 3 5 
Total 46 24 18 88 
3 Results 
Of 109 piriform sinus cancer patients, 88 ultimately died (81 %); that is, 46/55 
(84%) of the RT-1 patients, 24/28 (86%) of the RT-2 patients, and 18/26 (69%) of the 
RT-S patients. The cause of death for all 88 patients is listed in Table 3. The influ-
ence of stage on the probability of locoregional relapse-free survival and overall sur-
vival at 3,5, and 10 years is illustrated in Table 4. 
Table 5 presents the number of patients per treatment group failing locally, 
regionally, and with distant metastasis; in Table 6 the type and sequence of relapse 
are given. Of the relapsing patients only 6/37 (16%) of the RT-l group, 1/24 (4%) of 
the RT-2 group, and none (0/11) of the RT-S group survived. 
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Figure 1. Patients (n=109) with piriform sinus cancers treated between 1973 and 1984 in the 
DDHCC/UHR-D. Upper left panel: actuarial locoregional relapse-free survival; upper right panel: 
relapse-free survival; lower left panel: overall survival; lower right panel: disease-free survival. In all 
panels the survival is presented for each treatment subgroup (RT-1, RT-2, RT-S) separately. 
Figure 1 depicts the actuarial locoregional relapse-free survival, the relapse-free 
survival, the overall survival, and the disease-free survival at 10 years for 109 piri-
form sinus cancer patients, stratified for the treatment groups RT-l, RT-2, and RT-S. 
Figure 2 shows similar actuarial survival curves as depicted in Figure 1, now for early-
stage piriform sinus cancers (Tl ,2NO) as opposed to more advanced tumor stages 
(stage III/IV). 
Table 4. Piriform sinus cancer 1973-1984 DDHCC/UHR-D 
LR-RFS 
Tumor Stage (3-year) 
T1NO 0.625 
T2NO 0.500 
Stage 1/11 0.559 
Stage III/IV 0.352 
Total 0.393 
4 Discussion 
4.1 General Aspects 
OS LR-RFS OS LRFS OS 
(3-year) (5-year) 
0.571 0.625 
0.643 0.417 
0.619 0.497 
0.261 0.315 
0.330 0.351 
(5-year) 
0.429 
0.500 
0.476 
0.226 
0.274 
(10-year) 
0.625 
0.417 
0.497 
0.280 
0.324 
(10-year) 
0.500 
0.286 
0.135 
0.172 
As has been reported previously, there is a constant force of mortality due to all 
causes of death during the years of follow-up in cancer of the head and neck. In the 
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present series this phenomenon is substantiated by the difference between the 
relapse-free survival and overall survival curves (Figures. 1 and 2), and by the caus-
es of death; that is, 30% (26/88) of the patients died of nontumor related causes (5 
unknown, 21 nonprimary tumor-related) (Table 3). 
Table 5. Piriform sinus cancer 1973-1984 DDHCC!UHR-D 
RT-I 
RT-II 
RT-S 
All 
Local Failure 
28 (51) 
21 (75) 
2 (8) 
51 (47) 
Regional Failure 
13 (24) 
13 (46) 
9 (35) 
35 (32) 
Distant Failure 
9 (16) 
4 (14) 
3 (12) 
16 (15) 
With regard to the treatment-related type of morbidity, the locoregional treat-
ment of piriform sinus cancer by EBRT alone has the advantage over surgery of 
organ sparing; that is, by preserving the natural swallowing mechanism and speech. 
However, this could obviously be a trade-off against the chance for cure. In gener-
al, given the results reported in the current literature on cancer of piriform sinus 
proper for the advanced tumor stages, surgery combined with EBRT seems to offer 
increased locoregional control rates and survival over EBRT alone (3,4). Some cen-
ters even emphasize the feasibility of preservation of the larynx and optimal tumor 
control by a surgical approach for some of the early lesions (9,10). However, in gen-
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Figure 2. Patients (n=109) with piriform sinus cancers treated between 1973 and 1984 in the 
DDHCC/UHR-D. Upper left panel: actuarial locoregional relapse-free survival; upper right panel: 
relapse-free survival; lower left panel: overall survival; lower right panel: disease-free survival. In all 
panels the survival is presented for early (stage 1111) and advanced tumor stages separately. 
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eral for the early staged lesions the matter seems to be more controversial, that is, 
institutional preferences differ between surgery and EBRT alone (9-13). 
Unfortunately, there is no randomized trial comparing conservation surgery and/or 
EBRT alone for stage I and II piriform sinus cancer; at best, one can compare the 
results with the data reported in the current literature. For instance, Marks and col-
leagues (9) reported local control in 70 out of 80 (88%) piriform sinus cancers treat-
ed by preoperative EBRT combined with partial pharyngolaryngectomy; 
Vandenbrouck and colleagues (10) obtained local control in 16/18 (89%) piriform 
sinus cancers treated by conservation surgery. With respect to T1 and T2 piriform 
sinus cancers treated by EBRT alone, Bataini and coworkers (11) achieved local con-
trol in 68% (61/90) and in a series reported by Dubois and coworkers (12) 44/60 
(73%) of T1/T2 tumors were controlled. In a recent paper by Mendenhall and 
coworkers (13), a local control rate of 85% (62/73) was observed in T1/T2 piriform 
sinus lesions treated by EBRT only. Finally, from these data it is apparent that the 
likelihood of survival for EBRT alone was similar to that after conservation surgery. 
Table 6. Piriform sinus cancer 1973-1984 DDHCC/UHR-D 
Sequence of Relapse RT-I RT-II RT-S Total 
Local 18 10 1 29 
Regional 2 3 6 11 
Distant 5 6 
Local --1 Regional 7 6 14 
Regional --1 Local 1 2 
Local --1 Distant 2 
Regional --1 Distant 2 3 
Distant --1 Regional 
Local --1 Regional --1 Distant 3 4 
Total 37 24 11 72 
4.2 Stage III/IV Piriform Sinus Cancer: Present Series 
In our series 24/88 (27%) of the patients with advanced tumor stages were treat-
ed by EBRT and surgery (RT-S treatment group); moreover, 24/26 (92%) of the RT-
5 patients had stage III/IV cancers. For the RT-S treatment group an actuariallocore-
gional relapse-free survival of about 60% and an overall survival of approximately 
40% at 5 years was found (Figure 1). Patients with advanced tumor stages (n ~ 38) 
and thought to be eligible for EBRT only (good responders, RT-1) had a significant-
ly worse locoregional control rate and survival; that is, a locoregional relapse-free 
survival of 40% and an overall survival of approximately 20% (Figure 1). A multi-
variate Cox regression analysis was performed with the endpoints locoregional 
relapse-free survival, overall survival, and disease-free survival with covariate treat-
ment groups (RT-1, RT-2, and RT-S), T stage, N stage (Table 7). The most important 
prognostic factor appeared to be N stage, with hazard ratios of 1.16 (N1), 2.2 (N2), 
and 3.3 (N3). The RT-S treatment group fared best, with a hazard ratio of 0.5. 
Application of the Cox model (14) showed that the risk of relapse for the T3,4 
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patients was 1.3 times higher as opposed to the T1 ,2 patients. So, in conclusion, this 
analysis supports current literature data for stage III/IV piriform sinus cancers to be 
treated preferably by surgery combined with EBRT if the aim is optimal chance for 
control of the primary cancer and given the patient is a suitable candidate indeed 
for a (major) surgical procedure. It is of relevance, in this respect, that in this series 
of 88 patients with stage III/IV piriform sinus cancers, 26 poor-responding tumors 
were considered unsuitable for surgery at the time because of their inoperability 
perse, overall poor medical condition or patient refusal and were, consequently, 
treated by EBRT (RT-2 group). This selection bias in the treatment options for 
advanced head and neck tumors favoring EBRT for patients for instance with a low 
Karnofsky status, is a well-known general phenomenon, and it cannot be excluded 
that this might have unfavorably influenced the overall treatment results by EBRT 
alone. 
Table 7. Piriform sinus cancer 1973-19B4 DDHCC/UHR-D 
Cox model 
Hazard ratio se p-value 
RT-I/II 1.654 0.452 0.068 
RT-S 0.556 0.204 0.113 
Nl 1.161 0.428 0.687 
N2 2.203 0.618 0.006 
N3 3.303 1.557 0.013 
T3,4 1.335 0.343 0.264 
4.3 Stage 1/11 Piriform Sinus Cancer: Present Series 
In our series, 19 of 21 (91 %) of T1 ,2NO piriform sinus cancers were treated by 
EBRT only. The locoregional control (approximately 60% at 5 years) and overall sur-
vival (approximately 40% at 5 years) of stage 1/11 piriform sinus cancers is significantly 
better as opposed to the results observed in the more advanced tumor stages treat-
ed by EBRT, but similar to the best results obtained in the present series, that is, for 
the patients of the RT-5 treatment group (Figures 1 and 2). The survival rates are not 
dissimilar to those reported in the literature (3,4,9-13). With regard to the control of 
the primary site: however, some papers did report higher local control rates for 
T1/T2 piriform sinus cancers with EBRT alone (13). 
This sort of comparison} however, is subject to various biases inherent to the eval-
uation of nonrandomized data. More importantly, given the study period, that is 
1973-1984, we feel there are a number of reasons to anticipate on a potential 
improvement in the results to be obtained, particularly by EBRT: 
4.3.1 Neck Control 
The impact of neck disease on locoregional control and survival is corroborated 
by the N stage being the most important prognostic factor in the multivariate Cox 
regression analysis in our series (hazard ratios 1.161-3.303; Table 7). Overall, a high 
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regional failure rate was observed in the irradiated patients as well as in the surgi-
cally treated patients; 24% in the RT-1, 46% in the RT-2, and 53% in the RT-S 
patients (Table 5). Since only 20 of 35 nodal relapses were concurrent at some point 
in time with a local relapse (Table 6), this high neck recurrence rate could not be 
explained solely by "re-seeding" from a failure at the primary site. We felt that an 
additional factor might have been, as has been discussed previously (15), the some-
what too low dose of radiation in the electively irradiated necks. Also, during the 
study period detection of neck nodes was done on clinical palpation. There are cur-
rently sufficient reliable data available showing that, with better diagnostic means 
(e.g., CT/MRI-scanning and ultrasound), more neck nodes can be detected at an 
earlier date (earlier stage) (16,17). We now routinely use ultrasound (combined with 
cytological aspirations), and pathologically positive nodes are treated by means of a 
(bilateral) neck dissection and/or higher (booster) doses of EBRT. 
4.3.2 Radiobiological Considerations 
There is some debate as to whether the initial tumor response is a good predic-
tor for either failure or control of the irradiated tumors (18-20). Also, there has been 
some concern expressed in the current literature of accelerated repopulation of 
clonogenic tumor cells after a lag period of about 4 weeks (21-23). The average split 
period in our uRT-selective" protocol for piriform sinus cancer was 4-6 weeks. In 
order to improve the results, we have now abandoned split course regimes in all 
112 
6 2 1 S 
4 3 
40 (1,2) 
10 (4) 
30 (3) 
1301 (5,6) 
Figure 3. Anatomical data and tumor outline taken from CT slice of patient with 
piriform sinus cancer. Schematic diagram for treatmenl technique and dose dis-
tributions for piriform sinus cancer patients treated at the DDHCC/UHR-D 
between 1973 and 1984 by EBRT. TeChnique: The target volume is radiated by 
two parallel opposed wedged fields, using 4 MV photons (fields 1 and 2); the 
lower neck (nodes) by an abutted anterior photon portal (not depicted in the dia-
gram). The posterior part of the piriform sinus lies in close proximity to the ver-
tebra/cord. After a total dose of 40 Gy, the spinal cord is shielded in the 4 MV 
photon fields and the primary tumor is taken to 70 Gy (fields 5 and 6). An ipsi-
lateral low energy electron field (10 MeV) is added to the parallel opposed 
(blocked) photon fields to boost the posterior part of the primary tumor to a dose 
of 70 Gy (field 3); in a number of patients the posterior contralateral neck was 
carried (electively) to a cumulative dose of 50 Gy (field 4). As can be seen from 
the diagram, using this technique part of the target volume could have been 
underdosed, in particular when dealing with bulky lesions. 
Figure 4. Example of stage IIff piriform sinus cancer treated by EBRT, using 3D 
conformal radiation therapy techniques. This tumor was hypothetically radiated by 
a 5-field technique using beam modifiers. As is demonstrated in this schematic 
diagram, the target volume (primary tumor) can be easily taken to a cumulative 
dose of 70 Gy without overdosing the normal tissues (compare also Figure 3). 
head and neck cancers. Moreover, we no longer use initial tumor responses to EBRT 
as a means of incriminating potential failures (18). 
4.3.3 Radiotherapy Techniques 
Over the years a lot of interest has been shown in increasing the tumor control 
rates by individually tailoring the radiation therapy fractionation regimes, albeit con-
ventional-, hyper- or accelerated fractionation and concomitant boost techniques. 
Although these individualized fractionation regimes certainly might prove to be of 
value (24), trying to improve on the EBRT techniques per se should also be under-
scored (25). The anatomy of the piriform sinus is complicated in the sense that part 
of the target volume lies in close proximity to the cord and parotid glands. Using a 
conventional strictly parallel opposed field technique, combining low energy (e.g., 
4-8 MV) photons and low energy electrons (e.g., 10 MeV), will have limitations in 
this respect. For example, let us compare a piriform sinus cancer to be irradiated by 
conventional EBRT techniques (Figure 3; diagram of actual CT slice of patient with 
piriform sinus cancer), as opposed to the same tumor mass now treated by three-
dimensional conformal EBRT, making use of beam modifiers (Figure 4). The target is 
defined as primary piriform sinus tumor and neck, including a 0.7 em margin for 
microscopic disease and positioning uncertainty. As is demonstrated in the schemat-
ic diagrams with the superimposed computed isodose lines, when using simple par-
allel opposed techniques, dose escalation of the tumor is difficult without the risk of 
surpassing the tolerance of the cord; xerostomia is inevitable because of the high 
doses delivered to the (parotid) glands. Moreover, for conventional dose levels (e.g., 
70 Gy), part of the target volume could be even underdosed. An improvement in 
dose distribution is shown in Figure 4, applying multiple beams with beam modi-
fiers, trying to confine the prescribed dose to the target volume only (three-dimen-
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Figure 5. Dose volume histograms for primary piriform sinus cancer, parotid 
gland (P) and cord (C), comparing conventional treatment technique (Figure 3; 
stipulated lines) and conformal EBRT using a 5-field technique with beam mod-
ifiers (Figure 4; solid lines). 
sional conformal therapy). The dose volume histograms given in Figure 5 illustrate 
that the target volume can now easily be taken to a cumulative dose of 70 Gy with-
out overdosing the normal (critica!} tissues. 
5 Conclusion 
From the present report it is concluded that the majority of piriform sinus cancers 
have stage III/IV disease and should preferably be treated by surgery combined with 
EBRT. Given the results obtained in stage 1/11 piriform sinus cancer treated by with 
EBRT alone, we feel that EBRT with conservation of the pharynx and larynx should 
not be discarded as a valid treatment option; moreover, one could even speculate 
that by improving on the radiation therapy techniques we might be able to achieve 
substantial higher locoregional control rates with less morbidity in the near future. 
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Simulation accuracy in radiotherapy for maxillary sinus tumors 
Purpose: To evaluate the accuracy and clinical importance of beam positioning during sim-
ulation of radiation treatment for tumors in the maxillary sinus. 
Methods and Materials: Five patients were prepared as if they were 10 be treated for a 
maxillary sinus tumor. A three-beam computed tomography (CT) scan-based computer plan 
was made for each patient. The location of the central beam axis of each beam was mea-
sured, relative 10 bony anatomical structures. A simulation was performed using the bony ref-
erences to position the radiation beams during simulation. After this, the simulation proce-
dure was repeated by the usc of a noninvasive external localization frame wilh a know accu-
racy and reproducibility within 2 mm margins. 
Results: When defining the clinical target volume as the known tumor with a 1 cm mar-
gin, three out of rive patients would suffer a partial geographical miss throughout the entire 
radiation Ireatment due to erroneous beam positioning at the simulation stage when using 
bony structures as a guide for beam positioning. The influence of these errors is analyzed as 
normal tissue complication and tumor control probabilities. 
Conclusion: When defining a planning target volume, one should consider a margin to cor-
recl for possible simulation errors. We advise the use of objective, external (and thus 
nonanatomical) landmarks as a reference during simulation to reduce this extra margin to a 
minimum. In case of simulation, using bony structures as a reference, an additional margin 
should be entered, depending on the simulation accuracy that can be obtained. 
Keywords: Maxillary sinus cancer, Radiotherapy, Treatment simulation, Accuracy, Local 
control, Complication. 
Introduction 
One of the major advances in clinical radiotherapy during the last 10 years has 
been the introduction of conformal beam therapy. This treatment modality requires 
a high precision in both preparation and the actual treatment stage. The complexi-
ty of radiation therapy for maxillary sinus tumors resembles conformal beam thera-
py to a certain extent: covering the target volume is largely restricted by the tumor-
surrounding normal tissues (14). Moreover, beam positioning during treatment sim-
ulation is hampered by the large amount of bony structures that can serve as a land-
mark, easily leading to a situation in which one cannot see the wood for the trees. 
Lack of accuracy in radiation treatment preparation for maxillary sinus tumors might 
therefore be a reason why these tumors recur in a large number of patients (up to 
80% of the patients are faced with local recurrence), even after a complete remis-
sion after radiotherapy alone or in combination with surgery or regional chemother-
apy (the so-called Sato's treatment) (19,20). Indications for the validity of this state-
ment are publications on the influence of the introduction of computed tomogra-
phy (eT) scanning in radiotherapy planning of maxillary sinus tumors, after which 
the local control rate and the survival of patients with a maxillary sinus tumor 
increased significantly (8,9,18,22). 
The high number of unexpected radiotherapy-related complications to tumor-
surrounding normal tissues is a second argument to consider radiation treatment 
preparation for maxillary sinus tumors suboptimal. We therefore tried to evaluate 
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Figure 1. Noninvasive external localization frame with 
patient fixed in position by a vacuum mask. A: parallel rods; 
B: Lucite triangle. 
the beam positioning accuracy during treatment simulation, one of the most critical 
steps in radiotherapy, because an error made at this stage will be repeated through-
out the entire treatment, largely influencing treatment outcome. 
2 Methods and Materials 
For the aim of the study, a noninvasive external localization frame was developed 
(16). This frame was used to compare beam positions as a result of simulation, based 
on bony anatomical landmarks with beam positioning based on objective, external 
(and thus nonanatomical) numeric references. 
The design of the frame is based on a concept similar to stereotactic frames used 
routinely in neurosurgery. In contrast to these frames, localization can be performed 
without computed calculation of coordinates by direct read-out of external numer-
ic references. 
The technique of this frame is described elsewhere (16). In brief, it consists of par-
allel graphite rods, located in the craniocaudal axis and parallel to the table top 
(Figure 1). These rods are depicted on the CT scan as points, serving as a reference 
in the anteroposterior and laterolateral direction (Figure 2). At one side of this frame 
a lucite triangle serves as a reference in the craniocaudal direction; this triangle is 
seen on the CT scan as a line with a certain length, depending on the location in the 
craniocaudal direction in which the CT scan is performed (Figures 1 and 2, B). The 
accuracy and the clinical reproducib"dity of beam positioning using this frame was 
found to be within 2 mm margins (16). 
Five patients were prepared as if they were treated for a maxillary sinus tumor. 
During each step of the procedure the patient was immobilized with a vacuum 
mask to assure reproducible patient positioning in the best achievable way (this is 
within 2 mm margins under optimal conditions (6,22,25). CT planning was per-
formed for a three-beam radiation technique, the planning target volume being 
confined to the maxillary sinus, the tuber maxillae, and the bottom of the orbita, all 
with a 1 em margin to cover subclinical disease. CT scans with the noninvasive 
external localization frame were performed every 5 mm (1). A three-dimensional 
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Figure. 2. CT-scan image of immobilized patient with the 
noninvasive external localization frame. (A) Parallel rods 
depicted as dots; (8) Lucite triangle depicted as a line. 
(3D) treatment plan was made with the Cadplan treatment planning system (2). One 
anterior and two lateral beams were chosen to adequately cover the target volume 
and beam blocks were positioned in the beam's eye view to reduce the dose of the 
surrounding normal tissues to a minimum. This resulted in a homogeneous irradia-
tion of the target volume to a total dose of 70 Gy, with a maximum dose of 20% to 
R R 
I / 
A 
Figure 3. (A) Three-beam computer-assessed 3D treatment plan (Cadplan, Oosetek-Varian); plane 
through eye lens (70 Gy prescribed dose at 90%, normalization according to ICRU). (B) Three-beam 
computer-assessed 3D treatment plan (Cadplan, Oosetek-Varian); central plane (70 Gy prescribed 
dose at 90%, normalization according to ICRU). 
121 
the contralateral lens of the eye and of 64% to the spinal cord (Figures 3a and 3b). 
Each patient was simulated according to his CT-based treatment plan, using the 
bony structures as a reference for beam positioning during simulation. At this stage 
the beam portal outlines were indicated on the patient to enable reproducible beam 
positioning throughout the entire treatment. To avoid introduction of a bias, the sim-
ulations were performed by radiation oncologists other than the authors. The non-
invasive external localization frame was used to check the accuracy of the simula-
tions. The advantage of this system over the use of radio-opaque catheters mount-
ed on a patient's mask is its ease in use and the addition of references in the cran-
iocaudal direction (24). 
The difference between beam positions, resulting from treatment simulation 
using bony references and beam positions as achieved by using the noninvasive 
external localization frame, was noted in the laterolateral and craniocaudal direc-
tion for the anterior portal, and in the anteroposterior and craniocaudal direction for 
the right and left lateral portal (all expressed in 0101). New dose distributions were 
calculated, applying these beam positioning errors on the computer plan of one 
patient, serving as the reference plan. 
Table 1. Beam position errors at time of simulation, detected by the nonin-
vasive eXLernal localization frame. SO = standard deviation; CC = cranio-
caudal, AP = anteroposterior, LL = laterolateral; ali expressed in mm 
Beam Left Right Anterior 
Patient 
no. CC AP CC AP CC LL 
-8 7 -8 16 -/3 3 
2 -10 6 -10 -8 -10 10 
3 14 3 14 0 14 11 
4 -"10 5 -1 () -2 -10 0 
5 13 -5 13 3 13 6 
Mean -0.2 3.2 -0.2 1.8 -0.2 6 
SD 1"1.2 4.3 11.2 8.0 11.2 4.1 
A dose volume histogram (DVH) analysis of these dose distributions was per-
formed, together with an analysis of normal tissue complication probability (NTCP) 
and tumor control probability (TCP) values. The TCPs were calculated from the 
DVHs according to the clinical response model of Goitein, also described by 
Munzenrider (5,15). The parameters (dose-response curve for maxillary sinus 
tumors) for this model were obtained from the data from the literature (2,11,13). 
The NTCPs were calculated according to the model by I<utcher, using the data of 
Emami, and fitted as described by Burman (1,3,12). 
3 Results 
The beam positioning errors made during simulation for maxillary sinus tumors 
are given for each patient and as an average in Table 1. Although the mean error 
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made for all patients is low, indicating that these errors occur at random, the indi-
vidual dislocation of the beams was unexpectedly large. In three out of the five 
patients (patients 1, 3, and 5) it was found to be more than 1 cm for at least one 
beam in at least one direction. This also becomes clear from the standard deviation 
for the errors in the three directions. Because the positioning error is introduced 
during simulation, the greatest error is the single absolute greatest error in whatever 
direction and not the mean error per patient in the three directions. It is then clear 
that three out of five patients will have a systematic error (in at least one direction) 
introduced of at least 1 cm. These patients would therefore suffer a partial geo-
graphical miss throughout the entire treatment when defining the clinical target vol-
ume as the known tumor with a 1 em margin. 
The possible clinical value of enhancing simulation accuracy in maxillary sinus 
tumors was assessed by the DVH, TCp, and NTCP analysis. All five patients were 
compared with the computer-assessed plan serving as the best achievable clinical 
result (the intended plan). In ideal circumstances, that is, treatment simulation iden-
tical to the computer plan (which can be achieved within 2 mm accuracy by the use 
of the noninvasive external localization frame), the DVH shows a very steep falloff 
from 100% to 0% at 70 Gy (Figure 4). The patients in whom simulation was per-
formed using bony landmarks as a reference for beam positioning clearly suffer from 
a partial geographical miss, as can be seen in their respective target DVH (Figure 4). 
As expected, the patient with the largest simulation error has the lowest TCP. As an 
average, the TCP for the five patients was about one-third (27%) of the TCP of the 
intended plan (78%, Table 2). 
Table 2. TCP- and NTCP values when simulated and treated according to 
treatment plan (intended plan: using the noninvasive external localization 
frame) or with simulation errors (patient 1-5: simulating by anatomical land-
marks), 
NTCP NTCP 
ipsilateral contralateral NTCP 
TCP eye lens eye lens spinal cord 
intended plan 0.776 1.000 0.072 0.000 
patient no. 1 0.413 0.618 0.007 0.000 
patient no. 2 0.225 0.016 0.002 0.001 
patient no. 3 0.088 1.000 0.997 0.013 
patient no. 4 0.472 0.070 0.001 0.000 
patient no. 5 0.159 1.000 0.966 0.004 
mean (1-5) 0.271 
As to the normal tissues, the contralateral eye lens, when irradiated according to 
the treatment plan, receives a dose well below its tolerance, which also holds for 
those patients with the smallest simulation errors. However, in the two patients with 
the largest beal11 positioning errors, the contralateral eye lens is irradiated to a con-
siderably higher dose, which is expressed in a large NTCP value (Table 2). 
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Figure 4. Dose volume histogram for the larget volume. Intended 
plan: simulated and treated according to treatment plan (noninvasive 
external localization frame). Patient 1-5: treated according to beam 
position errors of simulation (anatomical landmarks). 
In contrast, the right eye lens (which receives the full dose when irradiating 
according to the computer plan) was found to receive doses well below its tolerance 
level in the patients with the largest beam positioning errors (Table 2). The spinal 
cord in all cases was irradiated to a dose well below its tolerance due to the larger 
distance to the target volume (Table 2). 
4 Discussion 
Much attention is given to the daily (random) beam positioning accuracy during 
radiation treatment. This uncertainty factor is accounted for in the planning target 
volume, defined as the clinical target volume with a margin necessary to avoid a par-
tial geographical miss due to these daily beam or patient positioning errors (lCRU 
report no. 50). Virtually no information is found, however, about the magnitude and 
possible clinical relevance of errors made in the process of simulation when bony 
structures serve as a reference for beam positioning, a method still widely in use. 
Despite the considerable clinical influence of simulation errors, the reason for this 
lack of knowledge is unclear. The only publications dealing with the clinical impor' 
tance of radiation treatment preparation analyze the influence of the type of treat, 
ment technique on treatment outcome, but do not address the problem of errors in 
the transfer from CT to simulator (4,7,17). 
After constructing this "missing link" between a planning CT scan and localization 
x'ray film, we were able to evaluate the possible clinical importance of simulation 
errors. To study the influence on local control and side effects of potential beam 
positioning errors at the stage of simulation, we chose maxillary sinus tumors for a 
number of reasons. First, many radiation treatment techniques exist for these 
tumors, indicating the complexity of their irradiation. Second, these tumors have a 
high local recurrence rate, ranging between 20% and 70%, and partly depending on 
the treatment technique used (10,11,19). The highest local control rates are 
achieved by multimodality therapy in which high doses of radiation play an impor' 
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tant role. Any improvement in radiation quality might therefore result in a better 
treatment outcome, as shown by Kondo and Tsujii (8,9,23). They clearly showed 
that the introduction of CT scanning in the treatment of maxillary sinus tumors leads 
to higher local control and survival rates, probably due to a better target delineation. 
Finally, maxillary sinus tumors were used as a first test site because af the complex-
ity of the treatment simulation procedure, due ta the large amount of anatomical 
structures that may serve as a (mis)lead during simulation. We deliberately did not 
define an extra margin around the clinical target volume to correct for daily beam 
positioning errors, because we wanted to evaluate the influence of simulation errors 
only. This is in contrast to daily practice where a margin is chosen far daily beam 
and patient positioning errors without taking possible beam-positioning errars dur-
ing simulation into account. 
The results of our analysis are very much according ta the clinical results of radio-
therapy for maxillary sinus tumors. The beam positioning errors made during simu-
lation were unexpectedly high and, in the DVH and TCP analysis, appear to be of 
great clinical importance. All patients suffer more or less from a partial geographical 
tumor miss due to simulation inaccuracy. This is reflected in the mean TCP value, 
which is about one-third of the maximal TCP (78%) when simulating completely 
according to the computer-assessed plan. We do, however, like to stress that one 
cannot give any absolute value to these TCP data because little information exists on 
a dear dose effect on local control, due to the enormous variation in treatment tech-
niques (2,11,13). Our data show very clearly that simulation beam-positioning 
errors are of clinical importance and should be taken into account when defining a 
planning volume if anatomical landmarks are used during simulation. The addition-
al margin that should be chosen for this reason will probably vary according to 
tumor site and the treatment technique used. For instance, a partial geographical 
miss due to simulation beam-positioning errors when using anatomical structures as 
a reference is very unlikely in T1 laryngeal cancer. In contrast, conformal beam ther-
apy for a brain tumor with complex beam settings is more likely to give a significant 
partial geographical miss when using virtually absent anatomical landmarks as a sim-
ulation guide. 
With regard to the normal tissues it became clear that the NTCP value of the 
spinal cord in none of the patients reached above the tolerance level. The con-
tralateral eye lens, however, was shown to be irradiated to a level above tolerance 
in patients with the largest beam-positioning errors. One might argue that these 
patients will not develop any lens complication due to a local tumor, which will cer-
tainly recur early because these patients were shown to have the largest geographi-
cal miss. Interestingly, the ipsilateral eye lens which was planned to be irradiated 
above its tolerance level (NTCP for the computer plan equaled 1), was apparently 
spared in two patients, again due to simulation beam-positioning errors. If one takes 
into account the higher probability for local recurrence after protecting the ipsilat-
eral eye lens by a block, one could seriously question the use of these lens blocks 
(2,21,23). As a result of our study, it can be concluded that these blocks should be 
positioned with the highest care, preferably checked daily on a clinical basis. 
125 
5 Conclusions 
The planning target volume for maxillary sinus tumors should include an addi-
tional margin to correct for possible partial geographical misses due to simulation 
errors caused by the transfer from the CT to the simulator. This error is likely to be 
smallest when easy to use, objective, and external references (such as our noninva-
sive external localization frame) serve as a guide for beam positioning during simu-
lation. If anatomical landmarks are used during the entire process of CT scanning, 
treatment planning, and simulation as a reference, this extra margin will consider-
ably enlarge the treated planning target and thereby the treated volume. As a result, 
from our study, we advise that the use of anatomical landmarks during simulation 
be reduced to keep the margin around the clinical tumor volume (defined to 
account for set-up uncertainties) at a magnitude such that surrounding critical struc-
tures can still be spared from high radiation doses. 
The possible clinical relevance of simulation errors in tumor sites other than the 
maxillary sinus is the issue of investigations currently being undertaken at our insti-
tute. 
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Treatment portals for elective radiotherapy of the neck - an inventory in The Netherlands 
Purpose: To assess the variation in and the three-dimensional dosimetric consequences of 
treatment portals for elective neck irradiation. 
Materials and Methods: Radiation oncologists (n=16) from all major Head and Neck Co-
operative Croups in The Netherlands (n=11) were asked to delineate treatment portals on a 
lateral and an anterior simul<:ltion film in case of elect'lve neck irradiation for a T3NO tumor 
of the supraglottic larynx and a T2NO tumor of the mobile tongue. In addition, they had to 
define their target, i.e. which parts of the neck nodal regions they would choose to irradiate 
electively for these particular tumor sites. Subsequently, treatment portals were compared 
and evaluated using CT-data and a 3-dimensional (3D) treatment planning system. 
Results: Significant variations were found in the in the shapes and sizes of the applied 
l-rcatment techniques and portals. Also, among radiation oncologists who elected to irradiate 
the same lymph node regions, a significant variation in the delineated treatment portals was 
observed. As a consequence, substantial variations in treated volumes and in calculated nor-
mal tissue complication probabilities (NTCPs) for the parotid- and submandibular glands were 
observed. 
Conclusion: For the tumor sites studied there appears to be lack of standardization in the 
areas of the neck to be irradiated electively. The observed differences may have conse-
quences for the ultimate failure rate and particularly with regard to the side effects, e.g. the 
degree of xerostomia. It is argued that in the near future a more precise three-dimensional 
definition on CT of the lymph node regions in the neck might allow for a better standardiza-
tion of the treatment: portals and, in addition, for the development and application of con-
formal radiotherapy techniques for optimal sparing of the critical normal tissues (e.g. parotid-
and submandibular glands) with maximum tumor control probability. 
Keywords: Head and neck, Radiotherapy, Treatment portals, Elective radiation 
1 Introduction 
Elective irradiation of the NO neck has shown to be effective in eliminating sub-
clinical disease (1,6-9). Unfortunately, this treatment is not without morbidity; that 
is, xerostomia is usually experienced because of (partial) inclusion of the (major) sali-
vary glands in the treatment portals (10). 
The purpose of the present study was to assess the variation in the routinely 
applied treatment portals in case of elective neck irradiation. This was done through 
a nationwide inventory. To study the 3D consequences of the observed variation in 
treatment portals, the portals were compared and evaluated using CT-scans and a 
3D treatment planning system. 
In a recent study, Leslie and Dische showed that the radiation-induced reduction 
in pre-treatment parotid salivary flow is dependent on the percentage of parotid 
gland volume irradiated (5). For this reason, in this study special attention is also 
given to the potential consequences of the observed variations in the cranial and 
ventral boundaries of the applied lateral parallel opposed portals. 
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Figure 1. Right lateral (a) and anterior (b) simulation 
film with the portals of the first responding radiation 
oncologist for a T3NO supraglottic larynx cancinoma 
(SgL) and a T2NO mobile tongue cancinoma (MbT). 
2 Materials and Methods 
This study is based on a commonly used radiation technique in head and neck 
cancer, that is, the use of lateral parallel opposed portals with or without an abutted 
low-anterior radiation field. For this purpose, right lateral- and anterior simulation 
films and a set of CT-slices of a patient, who was previously treated in our depart-
ment, were used. Both the simulation films and the CT-scans were made in treat-
ment position. The films were taken using a focus-to-film distance of 145 cm; CT 
slices were obtained from the base of skull down to the clavicles, using a slice dis-
tance of 5 mm. 
Copies of the simulation films were sent to 16 experienced head and neck radi-
ation oncologists in 11 departments of radiation oncology in The Netherlands. In an 
accompanying letter the radiation oncologists were asked to participate in a small 
survey regarding the size and shape of neck portals used for two different tumor 
sites, supposing that the local treatment policy was to electively irradiate (parts of) 
the neck. So, the question posed was really two-fold: firstly, to delineate the treat-
ment portals covering neck (and primary tumor), assuming that this patient had a 
T3NO carcinoma of the supraglottic larynx or a T2NO carcinoma of the mobile 
tongue. Secondly, to indicate which parts of the neck, i.e. high- (upper)-, mid-, 
lower-jugular, and posterior neck lymph node regions they intended to irradiate 
electively for these two clinical indications. As the investigation was focused at 
studying the consequences of 'routine' radiotherapy treatment techniques com-
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monly used in any radiation therapy department treating head and neck cancer 
patients, participating radiation oncologists were not given access to the CT-data of 
the patient in treatment position at the time of delineating the treatment portals. 
All treatment portals were imported in the 3D planning system CADPLAN 
(Varian-Dosetek, Finland). Dose distributions were calculated using the CT-data of 
the patient in treatment position, beam data of a 6 MV photon beam and a pre-
scribed dose of 46 Gy. The dose applied by the lateral parallel opposed portals was 
prescribed to the midplane of the patient; in case of an anterior portal for irradia-
tion of the lower part of the neck, this dose was prescribed at a depth of 3 cm. 
Dose-volume histograms (DVHs) for the body outline were generated to calculate 
treated volumes, defined as the volumes absorbing more than 95% of the prescribed 
dose (3). In addition, using the DVHs of the parotid and submandibular glands, 
NTCPs were calculated (2,4). For calculation of the NTCPs of the submandibular 
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Figure 2. The delineated treatment portals of all participating radiation oncologists superim-
posed in beam's eye view on the patient anatomy, Le. the patient outline and the submandibu-
lar and parotid glands for the lateral portals and the patient outline and the clavicles for the ante-
rior portals. Technique I: lateral parallel opposed portals only. Technique II: lateral parallel 
opposed portals in combination with an anterior porlal. The scale (5 cm) relates to a distance of 
100 cm from the focus. 
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Figure 3. Treated volumes, i.e. volumes absorbing more than 95% of the prescribed dose for 
Techniques I (open bars) and Technique II (closed bars), in combination with minimum, maxi-
mum and median values. 
glands (not specified in the parameter list of Burman et al.), the same parameters as 
used for the parotid glands were implemented (2). 
134 
Supraglottic Larynx 
a b Q + +2lr V+ :: h;9h'I"9 = 
mid-Jug 
low-jug 
c 
e 
posterior 
Mobile Tongue 
d 
+ + lfii ~v~ 
high-jug 
mid-jug 
low-jug 
posterior 
Figure 4. Lateral parallel opposed treatment portals of Figure 2 (Technique I 
only), grouped by similar treatment intention {see also Table 1}. In each panel, 
the inclusion (+) or exclusion {-} of high-, mid-, lower-jugular, and posterior 
lymph node regions is indicated. The scale (5 cm) relates to a distance of 100 
cm from the focus. 
3 Results 
As an example of the generally used treatment portals, in Figure 1, the delineat-
ed portals of the first responding radiation oncologist are shown. In this case, for the 
T3NO supraglottic larynx carcinoma (SgL), only lateral parallel opposed portals are 
used (Technique I). For the T2NO mobile tongue carcinoma (MbT), lateral parallel 
opposed portals are used in combination with an anterior portal for the lower part 
of the neck with shielding of the larynx (Technique II). 
In Figure 2, the treatment portals of all participating radiation oncologists, subdi-
vided according to treatment site and applied treatment technique, are shown in 
beam's eye view. For both techniques and sites, a large variation in size and shape 
of the portals can be observed. 
The treated volumes resulting from the volumetric calculations are displayed in 
Figure 3. A substantial range in the treated volumes is observed: for the supraglottic 
larynx carcinoma a range varying from 270 to 1490 em3, for the mobile tongue a 
range varying from 310 to 1320 cm3. Table 1 shows, for all radiation oncologists 
combined, the target they selected to treat for the two studied tumor sites. For the 
supraglottic larynx carcinoma, all radiation oncologists apparently elected to irradi-
ate the high- and mid-jugular neck region, with 10 out of 16 irradiating the lower 
jugular region as welL However, none of the radiation oncologists chose to treat the 
posterior neck nodes. For the mobile tongue carcinoma a larger variation was 
found; that is, only the high-jugular nodes (xl), or the high- and mid-jugular nodes 
(x5), or the high-, mid- and lower-jugular nodes (x8), or all jugular lymph node 
regions, the posterior nodes inclusive (x2), were irradiated. The high- and mid-jugu-
lar nodes were treated by lateral parallel opposed fields; for the irradiation of the 
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Figure 5. Left and right parotid and submandibular gland NTCPs for a prescribed dose of 46 Gy to the 
neck. 
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lower jugular neck nodes, for both primaly sites either Technique I or Technique II 
was apparently used. 
In Figure 4 the lateral parallel opposed portals are depicted in case of supraglot-
tic laryngeal carcinoma (panels a and b) or mobile tongue carcinoma (panels c-f) for 
radiation oncologists using Technique I. The portals were grouped according to the 
target volume the radiation oncologists had elected to irradiate (Table 1). As is clear-
ly shown by panels a-d, the portals still demonstrate a large variation in shape and 
size, that is even when the radiation oncologists selected similar targets. 
Table 1. Inventory of selected target volumes. An inventory of selected tar-
get volumes by 16 radiation oncologists, in case of elective irradiation of 
T3NO supraglottic laryngeal carcinoma and T2NO mobile tongue carcinoma. 
The radiation oncologists are nurnbered according to arrival date of 
response. The proposed treatment technique is indicated with I or II 
(Technique I: lateral paraliel opposed portals only; Technique II: lateral par-
allel opposed portals in combination with an anterior portal). The intention 
of the radiation oncologists to irradiate/not to irradiate the four defined 
lymph node areas (high-, mid-, lower jugular, and posterior) is indicated with 
+ or-. 
Carcinoma Radiation oncologist 
2 3 4 5 6 7 8 91011·1213141516 
Supraglottic Larynx (T3NO) 
Treatment technique II II II I I II II I 
High-jugular + + + + + + + + + + + + + + + + 
Mid-jugular + + + + + + + + + + + + + + + + 
Low-jugular - + + - + - + + + + - - + + + -
Posterior - - - - - - - - - - - -
Mobile Tongue (T2NO) 
Treatment technique II II II II II II II II 
High-jugular + + + + + + + + + + + + + + + + 
Mid-jugular + + - + + + + + + + + + + + + + 
Low-jugular + - - - + - + + + + + - + + + -
Posterior + - + -
In Figure 2, a substantial variation in the position of the boundaries of the treat-
ment portals at the level of the major salivalY glands is seen. Since parotid glands 
exhibit a large volume effect, a large variation in calculated salivary gland NTCP is 
found (Figure 5) (2,5). Similar types of observations can be made for the sub-
mandibular glands (Figure 5). The NTCPs for the T3NO supraglottic larynx are on 
average lower (0%-50%) than for the T2NO mobile tongue (20-70%). 
4 Discussion and conclusions 
In this study, large variations in applied treatment portals for elective irradiation 
of the neck in cancer of the supraglottic larynx or mobile tongue have been found. 
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To some extent, this stems from apparent disagreement as to which parts of the neck 
(high-, mid- and lower-jugular, and posterior) are to be irradiated. However, impor-
tantly, there are also major variations in the shape and size of the lateral parallel 
opposed portals selected to treat similar lymph node regions, that is, the anticipat-
ed precise location of the high-, mid- and/or lower-jugular lymph node regions 
seems uncertain. This could result in large variations in the morbidity of the treat-
ment, e.g. degree of xerostomia. In addition, a mismatch between target and treat-
ed volume obviously may result, in case of a geographical miss, in an increased fail-
ure rate. 
Therefore, a standardization of the target volume seems warranted. This applies 
both to the lymph node regions to be irradiated for a particular primary tumor site 
in the head and neck, as well as to the exact location (boundaries) of these regions. 
We feel that the development of a three-dimensional CT target volume definition, 
based on the already established surgical definitions for lymph node levels I-VI, 
might solve part of this problem (11,12). Firstly, it allows for an optimal design of 
treatment portals, provided agreement exists on the lymph node regions to be treat-
ed. Secondly, a three-dimensional target volume allows for the development and 
evaluation of more conformal radiotherapy (CRT) techniques for (elective) neck irra-
diation. Hence, it may be possible to substantially reduce the occurrence and/or 
severity of xerostomia resulting from elective radiotherapy of the neck, while main-
taining a high tumor control rate. In fact, the establishment of CT definitions of the 
lymph node regions and development of 3D CRT techniques of the neck is the sub-
ject of an ongoing study in our institute. 
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3D 
AP 
BEV 
C 
CC 
CC-RT 
CD-i 
CRT 
CT 
CTV 
DVH 
GTV 
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IV 
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MT 
MV 
N,NO 
ND 
NP 
NTCP 
NTD 
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PS 
PTV 
PTV-a 
S 
SC 
SC-RT 
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SL 
T, T2, T3 
TCP 
TV 
US 
USFNAC 
th ree-d i mensional 
antero-posterior 
beam's eye view 
cord 
cranio-caudal 
continuous course radiation therapy 
compact disc interactive 
conformal radiation therapy 
computed tomography 
clinical target volume 
dose volume histogram 
gross tumor volume 
international commission on radiation units 
irradiated volume 
latero-Iateral 
megaelectronvolt 
magnetic resonance imaging 
mobile tongue 
megavolt 
TNM classification 
neck dissection 
nasopharynx 
normal tissue complication probability 
normalized treatment dose 
parotid gland 
piriform sinus 
planning target volume 
planning target volume adjusted 
submandibular gland 
spinal cord 
split course radiation therapy 
standard deviation 
supraglottic larynx 
TNM classification 
tumor control probability 
treated volume 
ultrasound 
ultrasound fine needle aspiration cytology 
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Summary 
The curability of patients with tumors in the head and neck is dependent, among 
other factors, on the presence of lymph node metastases in the neck, i.e. the N-
stage of the disease. If the lymph nodes are not clinically palpable or detectable by 
diagnostic means such as CT, MRI scanning or ultrasound investigation (NO neck), 
the potential for subsequent development of lymph node metastasis dictates 
whether the neck should be treated electively. This thesis deals with radiation ther-
apy as a single modality treatment for the NO neck. 
The major side effect of elective neck irradiation is the dry mouth syndrome 
(xerostomia) due to damage to the salivary glands, with resulting dental caries, swal-
lowing disorders and speech disturbances. In many institutions, elective neck irradi-
ation is the preferred treatment for patients with tumors in the head and neck when 
the probability of subclinical disease is considered to exceed 10-20%. It is of utmost 
importance, therefore, to try and reduce the side-effects of radiation therapy. 
With the introduction of CT planning systems and the development of 3D con-
formal radiation therapy, it has become feasible to deliver adequate doses of radia-
tion to the target (neck) whilst, at the same time, saving (parts of) the salivary glands 
from doses exceeding tolerance. A prerequisite for such techniques is the need for 
an exact knowledge of the target, i.e. the elective neck, which has to be depicted 
on every planning CT slice. 
The main goal of this thesis was to develop and present a 3D CT definition of the 
clinical target volume of the clinically negative neck and also demonstrate that this 
definition allows the development of conformal (3D) radiotherapy techniques which 
adequately cover the primary tumor and the neck, whilst sparing the major salivary 
glands. An additional goal was the creation of an interactive compact disc (CD-i) for 
confirmation of the CT target definition, for studying isodose distributions of 3D 
radiotherapy techniques, and for educational purposes. 
Chapters 2 and 3 describe the background of this study. In Chapter 2, clinical 
aspects of lymph node involvement of the neck in head and neck tumors are sum-
marized. The different diagnostic methods to detect these lymph nodes are shown, 
as are the ways to treat the neck electively. It is concluded, as mentioned earlier, that 
elective treatment of the NO neck is mandatory when the risk of subclinical disease 
in the neck is substantial. Fundamental aspects of radiotherapy (e.g. the ICRU-50 
recommendations for target definition, dose-response relationships for the primary 
tumor site and the NO neck, side effects of elective neck irradiation) are also dis-
cussed. A number of basic principles and the expected benefits of conformal radio-
therapy are described. A dose-response relationship has been shown for many 
tumors of the head and neck, i.e., suboptimal doses of radiotherapy are detrimen-
tal for clinical outcome. Certain primary tumors, e.g. piriform sinus tumors, can only 
be adequately irradiated using conformal radiotherapy techniques. A prerequisite 
for the clinical use of these sophisticated conformal techniques is good quality assur-
ance. The importance of verification of patient positioning with portal imaging tech-
niques, in order to minimize patient setup errors during a treatment course is 
stressed. Some of the subjects in this chapter are further elaborated on in the first 
three addenda of this thesis. Chapter 3 describes the conventional techniques of 
145 
elective radiotherapy of a T2NO mobile tongue cancer and a T3NO supraglottic lar-
ynx cancer. In this summary of a nationwide study in The Netherlands, it was shown 
that there was a lack of standardization as to which areas of the neck had to be treat-
ed electively for these tumor sites. There was disagreement as to which anatomical 
regions had to be treated and also with respect to the delineation of the (2D) bor-
ders of these anatomical regions. Addendum D gives a full overview the study. 
In Chapter 4, the 3D definition of the target of the elective neck on CT is given. 
As the regional control rates for elective treatment of the neck are comparable for 
surgery and radiotherapy, the target for both modalities should be similar. Thus, the 
well established level definition of the Memorial Sloan-Kettering group served as a 
backbone for the CT target definition. Two anatomical studies were performed to 
translate soft tissue landmarks, given in a surgical (rotated) position of the head, into 
easily recognized borders on transversal CT slices. Small adjustments had to be 
made, mainly because of the different treatment positions of the head. All six levels 
were translated into six regions. The borders of these regions had to be available on 
all CT slices. Moreover, the way in which the definition had been accomplished had 
to be accessible. These demands could be fulfilled by the development of the 
"Definition Target" and the "Magnified Target" modules on the CD-i. 
In Chapter 5, conventional and conformal radiotherapy techniques are com-
pared for two primary tumor sites, i.e. an early-stage nasopharynx and an early-stage 
supraglottiC larynx cancer without detectable neck nodes. Using the definition of the 
CT target of Chapter 4, the target of the primary tumor and the neck regions to be 
treated for both sites were delineated on CT. The conventional treatment technique 
consists of two lateral parallel opposed fields with (nasopharynx) or without (supra-
glottic larynx) an abutted anterior field. A six-field conformal radiotherapy technique 
was developed for both primary tumors. Some constraints were imposed upon the 
conformal technique: firstly, it should be feasible in a busy radiotherapy department. 
Secondly, the coverage of the target should be comparable or superior to the con-
ventional technique. Finally, the major salivary glands should be spared in such a 
way that a clinical benefit is expected. Dose-distributions, dose-volume histograms, 
tumor control probabilities and normal tissue complication probabilities for the con-
ventional and conformal radiotherapy techniques were computed. It was possible 
to evaluate all data and this was accomplished by the implementation of the 
"Beam's Eye View" and the "Radiation Therapy" modules on the CD-i. It is con-
cluded that xerostomia can be reduced or avoided with conformal radiotherapy. 
The CD-i is obviously a very important element in this thesis as the answers to the 
questions addressed in the thesis have been implemented on CD-i. Chapter 6 shows 
the manner in which the data were incorporated on CD-i, how the 3D CT target 
definition can be verified, and how the data in Chapters 4 and 5 can be studied. As 
matching of the CT, MRI and anatomical data was performed in the second anatom-
ical study (Chapter 4), MRI data are also available. In addition, frontal and sagittal 
reconstructions were made for the CT and MRI slices, showing both the regions of 
the neck and isodose distributions. The CD-i concludes with the "Rationale" slides, 
which give an overview of the goals of this study and the "Materials and Methods" 
slides, which describe how the data in Chapters 4 and 5 were accumulated. 
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A CT target definition for elective irradiation of the neck has been developed and 
incorporated into a user-friendly CD-i. The work performed for this thesis indicates 
that a reduction in radiation morbidity (in particular, the dry mouth syndrome) is 
feasible. This CO-i (thesis) will hopefully provide a strong foundation for the conduct 
of clinical trials of conformal radiotherapy in head and neck cancer. 
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Samenvatting 
De genezing van patienten met tumoren in het hoofd-halsgebied hangt, naast 
andere factoren, af van de aanwezigheid van Iymfekliermetastasen in de hals, d.w.z. 
van het N-stadium van de ziekte. Indien de Iymfeklieren klinisch niet palpabel of 
detecteerbaar zijn met behulp van diagnostische middelen, zoals CT, MRI scanning 
of echografisch onderzoek (NO hals), bepaalt de bns op het ontstaan van Iymfe-
kliermetastasen of de hals electief behandeld dient te worden. Dit proefschrift gaat 
over radiotherapie van de hals (NO) als enige behandelingsmodaliteit. 
De belangrijkste bijwerking van electieve bestraling van de hals is het "droge 
mond syndroom" (xerostomie) ten gevolge van beschadiging van de speekselklieren, 
met als gevolg tandbederf, slikstoornissen en spraakstoornissen. In veel instituten is 
electieve bestraling van de hals de voorkeursbehandeling, indien de kans op sub-
klinische ziekte groter geschat wordt dan 10-20%. Het is daarom van het grootste 
belang te trachten de bijwerkingen van bestraling te verminderen. 
Met de introductie van CT planningssystemen en de ontwikkeling van 3D con-
formatie-radiotherapie is het haalbaar geworden het doelvolume adequaat te 
bestralen, terwijl tegelijkertijd de dosis op (een deel van) de speekselklieren de to-
lerantiedosis niet te boven gaat. Voor zulke technieken is een exacte kennis van het 
doelvolume, d.w.z. de electieve hals, vereist, en dient dit op iedere plannings-CT-
coupe afgebeeld te worden. 
Het voornaamste doel van dit proefschrift was de ontwikkeling en presentatie van 
een 3D CT definitie van het klinische doelvolume (clinical target volume) van de 
klinisch negatieve hals, alsook am aan te tonen dat het met deze definitie mogelijk 
is conformatie (3D)-radiotherapietechnieken te ontwikkelen, die de primaire tumor 
en de hals adequaat bestralen, met sparing van de grote speekselklieren. De creatie 
van een interactieve compact disc (CD-i) was een extra doel, am de CT-definitie van 
het doelvolume te bevestigen, isodoseverdelingen van 3D-radiotherapietechnieken 
!e bestuderen, en als leermiddel. 
De hoofdstukken 2 en 3 beschrijven de achtergrond van deze studie. In hoofd-
stuk 2 worden de klinische aspecten van halslymfeklieren bij hoofd-halstumoren 
samengevat. De verschillende diagnostische middelen om deze Iymfeklieren te 
detecteren worden getoond, evenals de manieren om de hals electief te behande-
len. De conclusie luidt, zoals eerder venneld, dat elect'leve behandeling van de NO 
hals aangewezen is, indien de kans op subklinische ziekte substantieel is. 
Fundamentele aspecten van de radiotherapie worden besproken (bijv. de ICRU-50 
aanbevelingen voor de definitie van het doelvolume, dosis-responsrelaties voor de 
primaire tumor en de NO hals, bijwerkingen van electieve bestraling van de hals), 
evenals een aantal basispri nei pes en de verwachte voordelen van conformatie-
radiotherapie. Een dosis-responsrelatie is aangetoond voor vele tumorsoorten in het 
hoofd-halsgebied, d.w.z. niet-optimale bestralingsdoses hebben een nadelige 
invloed op het klinische resultaat. Bepaalde tumoren, zoals tumoren uitgaande van 
de sinus piriforme, kunnen aileen met conformatie-radiotherapietechnieken 
afdoende worden bestraald. Goede kwaliteitsbewaking is een noodzakelijke voor-
waarde voor he! klinisch gebruik van deze geperfectioneerde conformatietech-
nieken. Het belang van controle van de patientpositionering met behulp van portal 
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imaging technieken, orn instellingslouten gedurende de bestralingen te voorkornen, 
wordt onderstreept. Op somrnige van deze onderwerpen wordt verder ingegaan in 
de eerste drie bijlagen bij dit proefschrift. Hoofdstuk 3 geeft een beschrijving van de 
conventionele technieken bij de electieve bestraling van een T2NO carcinoom uit-
gaande van het beweeglijke deel van de tong en van een T3NO carcinoom uit-
gaande van het bovenste gedeelte van het strottehoofd. In deze samenvatting van 
een in Nederland uitgevoerde nationale studie werd aangetoond dat bij deze 
tumorlocaties niet standaard was vastgelegd welke gebieden in de hals electief 
behandeld dienen te worden. Er was geen overeenstemming over de te behande-
len anatomische gebieden, noch over de begrenzing van deze gebieden. Bijlage D 
geeft een volledig overzicht van de studie. 
In hoofdstuk 4 wordt de 3D-definitie van het doelvolume van de electieve hals 
op CT gegeven. Aangezien de controlepercentages voor electieve behandeling van 
de hals voor chirurgie en radiotherapie vergelijkbaar zijn, dient het doelvolume voor 
beide behandelingsmodaliteiten gelijk te zijn. Derhalve heelt de gevestigde "Ievel"-
definitie van de Memorial Sloan-Kettering groep als basis voor het doelvolume op 
CT gediend. am markeringen in de weke delen, weergegeven in een chirurgische 
(gedraaide) positie van het hoofd, te vertalen naar gemakkelijk te herkennen gren-
zen op transversale (dwarse) CT-opnamen, werden twee anatomiestudies verricht. 
Met name de verschillende behandelingsposities van het hoofd maakten kleine aan-
passingen noodzakelijk. Aile zes "levels" werden vertaald naar zes regio's 
("regions"). De grenzen van deze regio's moesten op aile CT-opnames beschikbaar 
zijn. Bovendien moest de manier waarop de definitie tot stand was gekomen, be-
grijpelijk zijn. Aan deze voorwaarden kon worden voldaan door het ontwikkelen 
van de modules "Definition Target" en "Magnified Target" op de CD-i. 
In hoofdstuk 5 worden conventionele en conformatie-radiotherapietechnieken 
vergeleken voor twee primaire tumorlocaties, nl. een carcinoom uitgaande van de 
neuskeelholte en een carcinoom uitgaande van het bovenste deel van het strotte-
hoofd zonder detecteerbare halslymfeklieren (be ide in een vroeg stadium van de 
ziekte). Gebruikmakend van de CT-definitie van het doelvolume uit hoofdstuk 4, 
werden het doelvolume van de primaire tumor en de te behandelen gebieden in de 
hals voor beide zijden vastgelegd op CT. De conventionele bestralingstechniek 
bestaat uit twee laterale, parallel opponerende bundels met Ineuskeelholte) en zon-
der (strottehoofd) een aangrenzend voorste veld. Voor beide primaire tumoren 
werd een zes-velden conforrnatie-radiotherapietechniek ontwikkeld. De confor-
matietechniek moest aan een aantal voorwaarden voldoen: ten eerste moet de 
techniek uitvoerbaar zijn binnen een drukke radiotherapie-afdeling. Ten tweede 
moest de behandeling van het doelvolume gelijkwaardig zijn aan of zelfs beter dan 
de conventionele techniek. Tenslotte moesten de grote speekselklieren zodanig ge-
spaard worden dat een goed klinisch resultaat verwacht kan worden. Voor zowel de 
conventionele als de conformatie-radiotherapietechnieken werden dosisdistribu-
ties, dosis-volumehistogrammen, kansen op tumorcontrole en op normale-weefsel-
complicaties berekend. Aile gegevens dienden geevalueerd te kunnen worden, het-
geen mogelijk was door te voorzien in de modules I'Beam's Eye View" en 
"Radiation Therapy" op CD-i. De conclusie luidt dat xerostomie met conformatie-
radiotherapie verminderd of zelfs vermeden kan worden. 
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De CD-i is duidelijk een zeer belangrijk onderdeel van dit proefschrift, aangezien 
de antwoorden op de vragen in dit proefschrift op de CD-i zijn terug te vinden. 
Hoofdstuk 6 toont de wijze waarop de gegevens zijn verwerkt op CD-i, hoe de 3D 
CT-definitie van het doelvolume kan worden geverifieerd, en hoe de gegevens van 
hoofdstukken 4 en 5 kunnen worden bestudeerd. Aangezien de CT-, MRI- en 
anatomische gegevens in de tweede anatomiestudie werden gekoppeld 
(hoofdstuk 4), zijn ook MRI-gegevens beschikbaar. Bovendien werden er frontale en 
sagittale reconstructies gemaakt van de CT- en MRI-opnames, die zowel de te 
behandelen regio's in de hals als de isodoseverdelingen laten zien. De CD-i laat 
tenslotte de dia's "Rationale" zien, die een overzicht geven van de doelen van deze 
studie en de dia's "Materials and Methods", die beschrijven hoe de gegevens in 
hoofdstukken 4 en 5 werden verzameld. 
Een CT-definitie van het doelvolume voor electieve bestraling van de hals werd 
ontwikkeld en op een gebruikersvriendelijke CD-i verwerkt. Het werk dat ten be-
hoeve van dit proefschrift werd verricht, laat zien dat een vermindering van de stra-
lingsbijwerkingen (met name van het "droge mond syndroom") haalbaar is. Hopelijk 
zal deze CD-i (dit proefschrift) een sterke basis vormen voor het uitvoeren van kli-
nische studies met conformatie-radiotherapie bij kanker in het hoofd-halsgebied. 
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